{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:52:28Z","timestamp":1793393548189,"version":"4.5.0"},"reference-count":408,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01752-9","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:58:13Z","timestamp":1762167493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies"],"prefix":"10.1186","volume":"18","author":[{"given":"Kexun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"3","key":"1752_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1752_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.","journal-title":"Mol Cancer"},{"issue":"10454","key":"1752_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","volume":"404","author":"ML Meyer","year":"2024","unstructured":"Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, J\u00e4nne PA, Peters S, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404(10454):803\u201322.","journal-title":"Lancet"},{"issue":"7","key":"1752_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002459","volume":"9","author":"AC Tan","year":"2021","unstructured":"Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, et al. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021;9(7):e002459.","journal-title":"J Immunother Cancer"},{"key":"1752_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216537","volume":"13","author":"P Garg","year":"2024","unstructured":"Garg P, Pareek S, Kulkarni P, Horne D, Salgia R, Singhal SS. Next-generation immunotherapy: advancing clinical applications in cancer treatment. J Clin Med. 2024;13:6537.","journal-title":"J Clin Med"},{"issue":"4","key":"1752_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2022","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022;10(4):1367\u2013401.","journal-title":"Genes Dis"},{"key":"1752_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1015200","volume":"12","author":"P Smita","year":"2022","unstructured":"Smita P, Narayan PA, Gaurav JK. Therapeutic drug monitoring for cytotoxic anticancer drugs: principles and evidence-based practices. Front Oncol. 2022;12:1015200.","journal-title":"Front Oncol"},{"key":"1752_CR8","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.3390\/cancers14102473","volume":"14","author":"V Foglizzo","year":"2033","unstructured":"Foglizzo V, Marchi\u00f2 S. Nanoparticles as Physically- and Biochemically-Tuned drug formulations for cancers therapy. Cancers (Basel). 2033;14:2473.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1752_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.20.02063","volume":"39","author":"A Magnuson","year":"2021","unstructured":"Magnuson A, Sedrak MS, Gross CP, Tew WP, Klepin HD, Wildes TM, et al. Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer. J Clin Oncol. 2021;39(6):608\u201318.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1752_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41571-025-01035-9","volume":"22","author":"S Zhao","year":"2025","unstructured":"Zhao S, Zhao H, Yang W, Zhang L. The next generation of immunotherapies for lung cancers. Nat Rev Clin Oncol. 2025;22(8):592\u2013616.","journal-title":"Nat Rev Clin Oncol"},{"key":"1752_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","volume":"4","author":"S Tan","year":"2022","unstructured":"Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2022;4:579\u201397.","journal-title":"JACC CardioOncol"},{"key":"1752_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Ther. 2024;9:175.","journal-title":"Signal Transduct Target Ther"},{"key":"1752_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12272-023-01447-0","volume":"46","author":"R Maiti","year":"2023","unstructured":"Maiti R, Patel B, Patel N, Patel M, Patel A, Dhanesha N. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Arch Pharm Res. 2023;46:361\u201388.","journal-title":"Arch Pharm Res"},{"key":"1752_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2230618","volume":"15","author":"HP Gerber","year":"2023","unstructured":"Gerber HP, Gangwar S, Betts A. Therapeutic index improvement of antibody-drug conjugates. MAbs. 2023;15:2230618.","journal-title":"MAbs"},{"key":"1752_CR15","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.21037\/tlcr-24-964","volume":"13","author":"H Zhou","year":"2024","unstructured":"Zhou H, Zeng Y, Hida T, Hsu R, Huang Y, Dong X. The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review. Transl Lung Cancer Res. 2024;13:3778\u201394.","journal-title":"Transl Lung Cancer Res"},{"key":"1752_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24:809\u201317.","journal-title":"Curr Oncol Rep"},{"key":"1752_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114408","volume":"161","author":"A Samantasinghar","year":"2023","unstructured":"Samantasinghar A, Sunildutt NP, Ahmed F, Soomro AM, Salih ARC, Parihar P, et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother. 2023;161:114408.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"1752_CR18","first-page":"1490","volume":"7","author":"PF Bross","year":"2001","unstructured":"Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, et al. Approval summary: Gemtuzumab Ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490\u20136.","journal-title":"Clin Cancer Res"},{"key":"1752_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/17474086.2019.1558399","volume":"12","author":"C Van Der Weyden","year":"2019","unstructured":"Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Brentuximab vedotin in T-cell lymphoma. Expert Rev Hematol. 2019;12:5\u201319.","journal-title":"Expert Rev Hematol"},{"key":"1752_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","volume":"73","author":"A Ballantyne","year":"2013","unstructured":"Ballantyne A, Dhillon S. Trastuzumab emtansine: first global approval. Drugs. 2013;73:755\u201365.","journal-title":"Drugs"},{"key":"1752_CR21","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s40265-020-01408-7","volume":"80","author":"KA Lyseng-Williamson","year":"2020","unstructured":"Lyseng-Williamson KA. Trastuzumab emtansine: a review of its adjuvant use in residual invasive HER2-positive early breast cancer. Drugs. 2020;80:1723\u201330.","journal-title":"Drugs"},{"key":"1752_CR22","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","volume":"77","author":"YN Lamb","year":"2017","unstructured":"Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77:1603\u201310.","journal-title":"Drugs"},{"key":"1752_CR23","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Moxetumomab pasudotox: first global approval. Drugs. 2018;78:1763\u20137.","journal-title":"Drugs"},{"key":"1752_CR24","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","volume":"79","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Polatuzumab vedotin: first global approval. Drugs. 2019;79:1467\u201375.","journal-title":"Drugs"},{"issue":"21","key":"1752_CR25","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","volume":"30","author":"MH Brave","year":"2024","unstructured":"Brave MH, Maguire WF, Weinstock C, Zhang H, Gao X, Li F, et al. FDA approval summary: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2024;30(21):4815\u201321.","journal-title":"Clin Cancer Res"},{"key":"1752_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80:501\u20138.","journal-title":"Drugs"},{"key":"1752_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bulcan.2023.04.006","volume":"110","author":"J Duval","year":"2023","unstructured":"Duval J, Zaanan A. New drug approval: Trastuzumab-deruxtecan in HER2 positive advanced gastric or gastroesophageal junction cancer after previous treatment with trastuzumab. Bull Cancer. 2023;110:739\u201340.","journal-title":"Bull Cancer"},{"issue":"8","key":"1752_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/oncolo\/oyae151","volume":"29","author":"GU Mehta","year":"2024","unstructured":"Mehta GU, Vellanki PJ, Ren Y, Amatya AK, Mishra-Kalyani PS, Pan L, et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. Oncologist. 2024;29(8):667\u201371.","journal-title":"Oncologist"},{"key":"1752_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.bulcan.2023.03.023","volume":"110","author":"V Gorgeu","year":"2023","unstructured":"Gorgeu V, Grellety T. New drugs approval: Trastuzumab-deruxtecan - HER2-low metastatic breast cancer. Bull Cancer. 2023;110:597\u20138.","journal-title":"Bull Cancer"},{"key":"1752_CR30","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Belantamab mafodotin: first approval. Drugs. 2020;80:1607\u201313.","journal-title":"Drugs"},{"key":"1752_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.anl.2025.01.005","volume":"52","author":"I Okamoto","year":"2025","unstructured":"Okamoto I. Photoimmunotherapy for head and neck cancer: a systematic review. Auris Nasus Larynx. 2025;52:186\u201394.","journal-title":"Auris Nasus Larynx"},{"key":"1752_CR32","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A. Loncastuximab tesirine: first approval. Drugs. 2021;81:1229\u201333.","journal-title":"Drugs"},{"key":"1752_CR33","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED. Disitamab vedotin: first approval. Drugs. 2021;81:1929\u201335.","journal-title":"Drugs"},{"key":"1752_CR34","unstructured":"Available. accessed on July 12, at https:\/\/www.firstwordpharma.com\/node\/1760623?tsid=4 (2025)."},{"key":"1752_CR35","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Tisotumab vedotin: first approval. Drugs. 2021;81:2141\u20137.","journal-title":"Drugs"},{"key":"1752_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","volume":"83","author":"YA Heo","year":"2023","unstructured":"Heo YA. Mirvetuximab soravtansine: first approval. Drugs. 2023;83:265\u201373.","journal-title":"Drugs"},{"key":"1752_CR37","unstructured":"Available. accessed on July 12, at https:\/\/www.businesswire.com\/news\/home\/20241203790598\/en (2025)."},{"key":"1752_CR38","unstructured":"Available. accessed on July 12, at https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer (2025)."},{"key":"1752_CR39","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40265-025-02185-x","volume":"85","author":"HA Blair","year":"2025","unstructured":"Blair HA. Datopotamab deruxtecan: first approval. Drugs. 2025;85:965\u201375.","journal-title":"Drugs"},{"key":"1752_CR40","unstructured":"Available at https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression (accessed on July 12, 2025)."},{"key":"1752_CR41","unstructured":"Available. accessed on July 12, at https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20250529142716124.html (2025)."},{"issue":"1","key":"1752_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, et al. Antibody-drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18(1):51.","journal-title":"J Hematol Oncol"},{"key":"1752_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.","journal-title":"Signal Transduct Target Ther"},{"key":"1752_CR44","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","volume":"114","author":"N Diamantis","year":"2016","unstructured":"Diamantis N, Banerji U. Antibody-drug conjugates\u2013an emerging class of cancer treatment. Br J Cancer. 2016;114:362\u20137.","journal-title":"Br J Cancer"},{"key":"1752_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33\u201346.","journal-title":"Protein Cell"},{"issue":"6","key":"1752_CR46","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/0008-5472.CAN-05-3973","volume":"66","author":"YV Kovtun","year":"2006","unstructured":"Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214\u201321.","journal-title":"Cancer Res"},{"key":"1752_CR47","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","volume":"10","author":"P Zhao","year":"2020","unstructured":"Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020;10:1589\u2013600.","journal-title":"Acta Pharm Sin B"},{"key":"1752_CR48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1752_CR49","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","volume":"77","author":"J Rios-Doria","year":"2017","unstructured":"Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, et al. Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res. 2017;77(10):2686\u201398.","journal-title":"Cancer Res"},{"key":"1752_CR50","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li H, Gou L, Li W, Wang Y. Antibody-drug conjugates: recent advances in payloads. Acta Pharm Sin B. 2023;13:4025\u201359.","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"1752_CR51","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1535-7163.MCT-17-0672","volume":"17","author":"KR Durbin","year":"2018","unstructured":"Durbin KR, Phipps C, Liao X. Mechanistic modeling of antibody-drug conjugate internalization at the cellular level reveals inefficient processing steps. Mol Cancer Ther. 2018;17(6):1341\u201351.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1752_CR52","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337.","journal-title":"Nat Rev Drug Discov"},{"key":"1752_CR53","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/978-981-13-7647-4_12","volume":"1141","author":"H Amawi","year":"2019","unstructured":"Amawi H, Sim HM, Tiwari AK, Ambudkar SV, Shukla S. ABC Transporter-Mediated Multidrug-Resistant cancer. Adv Exp Med Biol. 2019;1141:549\u201380.","journal-title":"Adv Exp Med Biol"},{"key":"1752_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108488","volume":"249","author":"J Dong","year":"2023","unstructured":"Dong J, Yuan L, Hu C, Cheng X, Qin JJ. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review. Pharmacol Ther. 2023;249:108488.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1752_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59802-w","volume":"10","author":"DJ Swartz","year":"2020","unstructured":"Swartz DJ, Singh A, Sok N, Thomas JN, Weber J, Urbatsch IL. Replacing the eleven native tryptophans by directed evolution produces an active P-glycoprotein with site-specific, non-conservative substitutions. Sci Rep. 2020;10(1):3224.","journal-title":"Sci Rep"},{"key":"1752_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1364494","volume":"11","author":"Y Gao","year":"2024","unstructured":"Gao Y, Wei C, Luo L, Tang Y, Yu Y, Li Y, et al. Membrane-assisted tariquidar access and binding mechanisms of human ATP-binding cassette transporter P-glycoprotein. Front Mol Biosci. 2024;11:1364494.","journal-title":"Front Mol Biosci"},{"issue":"8","key":"1752_CR57","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/1535-7163.MCT-22-0743","volume":"22","author":"W Zhou","year":"2023","unstructured":"Zhou W, Fang P, Yu D, Ren H, You M, Yin L, et al. Preclinical evaluation of 9MW2821, a site-specific monomethyl auristatin E-based antibody-drug conjugate for treatment of Nectin-4-expressing cancers. Mol Cancer Ther. 2023;22(8):913\u201325.","journal-title":"Mol Cancer Ther"},{"issue":"32","key":"1752_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302377","volume":"10","author":"X Hong","year":"2023","unstructured":"Hong X, Chen X, Wang H, Xu Q, Xiao K, Zhang Y, et al. A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer. Adv Sci. 2023;10(32):e2302377.","journal-title":"Adv Sci"},{"issue":"4","key":"1752_CR59","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/ijgc-2023-004924","volume":"34","author":"G Bogani","year":"2024","unstructured":"Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, et al. Mirvetuximab soravtansine-gynx: first antibody\/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer. Int J Gynecol Cancer. 2024;34(4):469\u201377.","journal-title":"Int J Gynecol Cancer"},{"key":"1752_CR60","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-22-0804","volume":"22","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Use of payload binding selectivity enhancers to improve therapeutic index of Maytansinoid-antibody-drug conjugates. Mol Cancer Ther. 2023;22:1332\u201342.","journal-title":"Mol Cancer Ther"},{"key":"1752_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00749","volume":"10","author":"P Liu-Kreyche","year":"2019","unstructured":"Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai Y. Lysosomal P-gp-MDR1 confers drug resistance of Brentuximab Vedotin and its cytotoxic payload monomethyl auristatin E in tumor cells. Front Pharmacol. 2019;10:749.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1752_CR62","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1535-7163.MCT-22-0013","volume":"21","author":"O Cabaud","year":"2022","unstructured":"Cabaud O, Berger L, Crompot E, Ad\u00e9laide J, Finetti P, Garnier S, et al. Overcoming resistance to anti-Nectin-4 antibody-drug conjugate. Mol Cancer Ther. 2022;21(7):1227\u201335.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1752_CR63","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10928-023-09877-5","volume":"51","author":"MP Choules","year":"2024","unstructured":"Choules MP, Zuo P, Otsuka Y, Garg A, Tang M, Bonate P. Physiologically based pharmacokinetic model to predict drug-drug interactions with the antibody-drug conjugate enfortumab Vedotin. J Pharmacokinet Pharmacodyn. 2024;51(5):417\u201328.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1752_CR64","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.22.651305","author":"JS Roth","year":"2025","unstructured":"Roth JS, Guo H, Chen L, Shen M, Gbadegesin O, Robey RW, et al. Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters. BioRxiv [Preprint]. 2025. https:\/\/doi.org\/10.1101\/2025.05.22.651305.","journal-title":"BioRxiv [Preprint]"},{"key":"1752_CR65","first-page":"150","volume":"49","author":"M Cianfriglia","year":"2013","unstructured":"Cianfriglia M. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of Gemtuzumab Ozogamicin. Ann Ist Super Sanita. 2013;49:150\u201368.","journal-title":"Ann Ist Super Sanita"},{"issue":"2","key":"1752_CR66","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1535-7163.MCT-24-0588","volume":"24","author":"WF Li","year":"2025","unstructured":"Li WF, Chiang MF, Weng HC, Yang JJ, Wu HS, Wu SY, et al. OBI-992, a novel TROP2-targeted antibody-drug conjugate, demonstrates antitumor activity in multiple cancer models. Mol Cancer Ther. 2025;24(2):163\u201375.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1752_CR67","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","volume":"122","author":"FW Hunter","year":"2020","unstructured":"Hunter FW, Barker HR, Lipert B, Roth\u00e9 F, Gebhart G, Piccart-Gebhart MJ, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br J Cancer. 2020;122(5):603\u201312.","journal-title":"Br J Cancer"},{"issue":"5","key":"1752_CR68","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","volume":"26","author":"R Chen","year":"2020","unstructured":"Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, et al. Inhibition of MDR1 overcomes resistance to Brentuximab Vedotin in hodgkin lymphoma. Clin Cancer Res. 2020;26(5):1034\u201344.","journal-title":"Clin Cancer Res"},{"issue":"6\u2013Sup","key":"1752_CR69","volume":"84","author":"CS Shia","year":"2024","unstructured":"Shia CS, Wen SN, Hsu RY, Tu JS, Chang HW, Li WF, et al. Abstract 7179: OBI-992, a novel TROP2 targeting antibody drug conjugate demonstrates superior in vivo PK\/PD properties and a favorable safety profile. Cancer Res. 2024;84(6\u2013Sup):4.","journal-title":"Cancer Res"},{"issue":"1","key":"1752_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010283","volume":"15","author":"RB Nielsen","year":"2023","unstructured":"Nielsen RB, Holm R, Pijpers I, Snoeys J, Nielsen UG, Nielsen CU. Combinational inhibition of P-glycoprotein-mediated etoposide transport by zosuquidar and polysorbate 20. Pharmaceutics. 2023;15(1):283.","journal-title":"Pharmaceutics"},{"key":"1752_CR71","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ejmech.2017.06.047","volume":"138","author":"P Joshi","year":"2017","unstructured":"Joshi P, Vishwakarma RA, Bharate SB. Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. Eur J Med Chem. 2017;138:273\u201392.","journal-title":"Eur J Med Chem"},{"key":"1752_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051158","volume":"10","author":"R Alves","year":"2022","unstructured":"Alves R, Gon\u00e7alves AC, Jorge J, Almeida AM, Sarmento-Ribeiro AB. Combination of elacridar with imatinib modulates resistance associated with drug efflux transporters in chronic myeloid leukemia. Biomedicines. 2022;10:1158.","journal-title":"Biomedicines"},{"issue":"3","key":"1752_CR73","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s10637-019-00806-3","volume":"38","author":"A Karbownik","year":"2020","unstructured":"Karbownik A, Soba\u0144ska K, P\u0142otek W, Grabowski T, Klupczynska A, Plewa S, et al. The influence of the coadministration of the P-glycoprotein modulator Elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. Invest New Drugs. 2020;38(3):574\u201383.","journal-title":"Invest New Drugs"},{"key":"1752_CR74","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ijbiomac.2019.01.195","volume":"128","author":"H Zhang","year":"2019","unstructured":"Zhang H, Jiang H, Zhang H, Liu J, Hu X, Chen L. Ribophorin II potentiates P-glycoprotein- and ABCG2-mediated multidrug resistance via activating ERK pathway in gastric cancer. Int J Biol Macromol. 2019;128:574\u201382.","journal-title":"Int J Biol Macromol"},{"key":"1752_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-375","volume":"8","author":"X Guo","year":"2008","unstructured":"Guo X, Ma N, Wang J, Song J, Bu X, Cheng Y, et al. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer. 2008;8:375.","journal-title":"BMC Cancer"},{"key":"1752_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107443","volume":"94","author":"L Wu","year":"2021","unstructured":"Wu L, Cai S, Deng Y, Zhang Z, Zhou X, Su Y, et al. PD-1\/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K\/AKT mediated P-gp expression. Int Immunopharmacol. 2021;94:107443.","journal-title":"Int Immunopharmacol"},{"key":"1752_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120463","volume":"298","author":"MDA Paskeh","year":"2022","unstructured":"Paskeh MDA, Saebfar H, Mahabady MK, Orouei S, Hushmandi K, Entezari M, et al. Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy. Life Sci. 2022;298:120463.","journal-title":"Life Sci"},{"key":"1752_CR78","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1080\/10717544.2022.2079771","volume":"29","author":"C Wang","year":"2022","unstructured":"Wang C, Li F, Zhang T, Yu M, Sun Y. Recent advances in anti-multidrug resistance for nano-drug delivery system. Drug Deliv. 2022;29:1684\u201397.","journal-title":"Drug Deliv"},{"key":"1752_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.561936","volume":"10","author":"JI Lai","year":"2020","unstructured":"Lai JI, Tseng YJ, Chen MH, Huang CF, Chang PM. Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics. Front Oncol. 2020;10:561936.","journal-title":"Front Oncol"},{"issue":"7","key":"1752_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071470","volume":"14","author":"SSK Yalamarty","year":"2022","unstructured":"Yalamarty SSK, Filipczak N, Li X, Pathrikar TV, Cotter C. Co-delivery of SiRNA and chemotherapeutic drug using 2C5 antibody-targeted dendrimer-based mixed micelles for multidrug resistant cancers. Pharmaceutics. 2022;14(7):1470.","journal-title":"Pharmaceutics"},{"key":"1752_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2022.113103","volume":"222","author":"T Yang","year":"2023","unstructured":"Yang T, Curtis S, Bai A, Young A, Derosier D, Ripley S, et al. CRISPR\/Cas9 targeting liposomes knocked down multidrug resistance proteins in brain endothelial cells as a model to predict potential pharmacoresistance. Colloids Surf B Biointerfaces. 2023;222:113103.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1752_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2021.102494","volume":"40","author":"J Halder","year":"2022","unstructured":"Halder J, Pradhan D, Kar B, Ghosh G, Rath G. Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer. Nanomedicine. 2022;40:102494.","journal-title":"Nanomedicine"},{"key":"1752_CR83","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/1061186X.2022.2069782","volume":"30","author":"S Md","year":"2022","unstructured":"Md S, Alhakamy NA, Sharma P, Ansari MS, Gorain B. Nanocarrier-based co-delivery approaches of chemotherapeutics with natural P-glycoprotein inhibitors in the improvement of multidrug resistance cancer therapy. J Drug Target. 2022;30:801\u201318.","journal-title":"J Drug Target"},{"issue":"7","key":"1752_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22791","volume":"35","author":"Q Yang","year":"2021","unstructured":"Yang Q, Nakamura T, Seto M, Miyagawa M, Xu W, Zhu B, et al. A multidrug resistance-associated protein inhibitor is a potential enhancer of the benzyl isothiocyanate-induced apoptosis induction in human colorectal cancer cells. J Biochem Mol Toxicol. 2021;35(7):e22791.","journal-title":"J Biochem Mol Toxicol"},{"key":"1752_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100795","volume":"59","author":"KM Hanssen","year":"2021","unstructured":"Hanssen KM, Haber M, Fletcher JI. Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: beyond pharmacological inhibition. Drug Resist Updat. 2021;59:100795.","journal-title":"Drug Resist Updat"},{"key":"1752_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/mtomcs\/mfab015","volume":"13","author":"SA Pearson","year":"2021","unstructured":"Pearson SA, Cowan JA. Glutathione-coordinated metal complexes as substrates for cellular transporters. Metallomics. 2021;13:mfab015.","journal-title":"Metallomics"},{"key":"1752_CR87","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber HP. Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther. 2016;15:2825\u201334.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1752_CR88","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"YF Chen","year":"2023","unstructured":"Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun (Lond). 2023;43(3):297\u2013337.","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"1752_CR89","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/1872312809666150602151922","volume":"9","author":"BQ Shen","year":"2015","unstructured":"Shen BQ, Bumbaca D, Yue Q, Saad O, Tibbitts J, Khojasteh SC, et al. Non-clinical disposition and metabolism of DM1, a component of trastuzumab emtansine (T-DM1), in Sprague Dawley rats. Drug Metab Lett. 2015;9(2):119\u201331.","journal-title":"Drug Metab Lett"},{"issue":"2","key":"1752_CR90","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/iju5.12696","volume":"7","author":"M Kotono","year":"2024","unstructured":"Kotono M, Kijima T, Takada-Owada A, Okubo N, Kurashina R, Kokubun H, et al. Increased expression of ATP-binding cassette transporters in enfortumab vedotin-resistant urothelial cancer. IJU Case Reports. 2024;7(2):173\u20136.","journal-title":"IJU Case Reports"},{"issue":"7","key":"1752_CR91","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.apsb.2020.12.002","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Huang S, Zhong W, Chen W, Yao B, Wang X. 3D organoids derived from the small intestine: an emerging tool for drug transport research. Acta Pharm Sin B. 2021;11(7):1697\u2013707.","journal-title":"Acta Pharm Sin B"},{"issue":"13","key":"1752_CR92","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.18632\/oncotarget.3414","volume":"6","author":"N Skrypek","year":"2015","unstructured":"Skrypek N, Vasseur R, Vincent A, Duch\u00eane B, Van Seuningen I, Jonckheere N. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan\/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. Oncotarget. 2015;6(13):10853\u201367.","journal-title":"Oncotarget"},{"issue":"1","key":"1752_CR93","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1248\/bpb.31.146","volume":"31","author":"S Itagaki","year":"2008","unstructured":"Itagaki S, Chiba M, Kobayashi M, Hirano T, Iseki K. Contribution of multidrug resistance-associated protein 2 to secretory intestinal transport of organic anions. Biol Pharm Bull. 2008;31(1):146\u20138.","journal-title":"Biol Pharm Bull"},{"key":"1752_CR94","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1111\/j.1476-5381.2011.01672.x","volume":"165","author":"C Fahrmayr","year":"2012","unstructured":"Fahrmayr C, K\u00f6nig J, Auge D, Mieth M, Fromm MF. Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012;165:1836\u201347.","journal-title":"Br J Pharmacol"},{"key":"1752_CR95","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.bioorg.2019.01.068","volume":"85","author":"MA Abou-Salim","year":"2019","unstructured":"Abou-Salim MA, Shaaban MA, Abd El Hameid MK, Elshaier YAMM, Halaweish F. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma. Bioorg Chem. 2019;85:515\u201333.","journal-title":"Bioorg Chem"},{"issue":"8","key":"1752_CR96","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/ijc.30870","volume":"141","author":"N Takegawa","year":"2017","unstructured":"Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141(8):1682\u20139.","journal-title":"Int J Cancer"},{"issue":"9","key":"1752_CR97","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-20-0222","volume":"19","author":"S Corbett","year":"2020","unstructured":"Corbett S, Huang S, Zammarchi F, Howard PW, van Berkel PH, Hartley JA. The role of specific ATP-binding cassette transporters in the acquired resistance to pyrrolobenzodiazepine dimer-containing antibody-drug conjugates. Mol Cancer Ther. 2020;19(9):1856\u201365.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1752_CR98","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41594-023-01176-4","volume":"31","author":"S Pourmal","year":"2024","unstructured":"Pourmal S, Green E, Bajaj R, Chemmama IE, Knudsen GM, Gupta M, et al. Structural basis of prostaglandin efflux by MRP4. Nat Struct Mol Biol. 2024;31(4):621\u201332.","journal-title":"Nat Struct Mol Biol"},{"issue":"9","key":"1752_CR99","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.3324\/haematol.2021.279761","volume":"107","author":"R Wolf","year":"2022","unstructured":"Wolf R, Grammbauer S, Palankar R, Tolksdorf C, Moritz E, B\u00f6hm A, et al. Specific inhibition of the transporter MRP4\/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets. Haematologica. 2022;107(9):2206\u201317.","journal-title":"Haematologica"},{"key":"1752_CR100","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ijbiomac.2020.06.106","volume":"161","author":"JPM Colavita","year":"2020","unstructured":"Colavita JPM, Todaro JS, de Sousa M, May M, G\u00f3mez N, Yaneff A, et al. Multidrug resistance protein 4 (MRP4\/ABCC4) is overexpressed in clear cell renal cell carcinoma (ccRCC) and is essential to regulate cell proliferation. Int J Biol Macromol. 2020;161:836\u201347.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"1752_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71181-w","volume":"10","author":"A Sahores","year":"2020","unstructured":"Sahores A, Carozzo A, May M, G\u00f3mez N, Di Siervi N, De Sousa Serro M, et al. Multidrug transporter MRP4\/ABCC4 as a key determinant of pancreatic cancer aggressiveness. Sci Rep. 2020;10(1):14217.","journal-title":"Sci Rep"},{"issue":"Pt 4","key":"1752_CR102","doi-asserted-by":"publisher","first-page":"136386","DOI":"10.1016\/j.ijbiomac.2024.136386","volume":"280","author":"RH Cervi\u00f1o","year":"2024","unstructured":"Cervi\u00f1o RH, G\u00f3mez N, Sahores A, Gouts A, Gonz\u00e1lez B, Shayo C, et al. Flurbiprofen inhibits cAMP transport by MRP4\/ABCC4 increasing the potency of gemcitabine treatment in PDAC cell models. Int J Biol Macromol. 2024;280(Pt 4):136386.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"1752_CR103","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1158\/1535-7163.MCT-04-0161","volume":"4","author":"MD Norris","year":"2005","unstructured":"Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, et al. Expression of multidrug transporter MRP4\/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther. 2005;4(4):547\u201353.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"1752_CR104","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02078-19","volume":"64","author":"I Ruiz","year":"2020","unstructured":"Ruiz I, Nevers Q, Hern\u00e1ndez E, Ahnou N, Brillet R, Softic L, et al. MK-571, a cysteinyl leukotriene receptor 1 antagonist, inhibits hepatitis C virus replication. Antimicrob Agents Chemother. 2020;64(6):e02078\u201319.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1752_CR105","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s13318-024-00908-1","volume":"49","author":"Y Shan","year":"2024","unstructured":"Shan Y, Cen Y, Xu X, Li P, Chen J, Nie Z, et al. The ATP-binding cassette transporter-mediated efflux transport of ganciclovir at the blood-brain barrier. Eur J Drug Metab Pharmacokinet. 2024;49(5):609\u201317.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"1752_CR106","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2003-02-0396","volume":"102","author":"RB Walter","year":"2003","unstructured":"Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML. Multidrug resistance protein attenuates Gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood. 2003;102(4):1466\u201373.","journal-title":"Blood"},{"issue":"6","key":"1752_CR107","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1021\/jm031011g","volume":"47","author":"S Wang","year":"2004","unstructured":"Wang S, Folkes A, Chuckowree I, Cockcroft X, Sohal S, Miller W, et al. Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance. J Med Chem. 2004;47(6):1329\u201338.","journal-title":"J Med Chem"},{"key":"1752_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117167","volume":"178","author":"Z Belhadj","year":"2024","unstructured":"Belhadj Z, Akther T, Wang Z, Xie J. Characterization of a deazaflavin analog as a potent inhibitor of multidrug resistance-associated protein 1. Biomed Pharmacother. 2024;178:117167.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1752_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49204-1","volume":"15","author":"Y Huang","year":"2024","unstructured":"Huang Y, Xue C, Bu R, Wu C, Li J, Zhang J, et al. Inhibition and transport mechanisms of the ABC transporter hMRP5. Nat Commun. 2024;15(1):4811.","journal-title":"Nat Commun"},{"key":"1752_CR110","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/biof.5520170111","volume":"17","author":"L Homolya","year":"2003","unstructured":"Homolya L, V\u00e1radi A, Sarkadi B. Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors. 2003;17:103\u201314.","journal-title":"Biofactors"},{"issue":"1","key":"1752_CR111","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S0959-8049(02)00447-1","volume":"39","author":"G Rappa","year":"2003","unstructured":"Rappa G, Gamcsik MP, Mitina RL, Baum C, Fodstad O, Lorico A. Retroviral transfer of MRP1 and gamma-glutamyl cysteine synthetase modulates cell sensitivity to L-buthionine-S,R-sulphoximine (BSO): new rationale for the use of BSO in cancer therapy. Eur J Cancer. 2003;39(1):120\u20138.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1752_CR112","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/10937404.2023.2246876","volume":"26","author":"C Dos Reis Oliveira","year":"2023","unstructured":"Dos Reis Oliveira C, Pereira JC, Barros Ibiapina A, Roseno Martins IR, de Castro E, Sousa JM, Ferreira PMP, et al. Buthionine sulfoximine and chemoresistance in cancer treatments: a systematic review with meta-analysis of preclinical studies. J Toxicol Environ Health B Crit Rev. 2023;26(8):417\u201341.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"1752_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113400","volume":"228","author":"H Tian","year":"2023","unstructured":"Tian H, Yu L, Zhang M, He J, Sun X, Ni P. Dextran-doxorubicin prodrug nanoparticles conjugated with CD147 monoclonal antibody for targeted drug delivery in hepatoma therapy. Colloids Surf B Biointerfaces. 2023;228:113400.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"5","key":"1752_CR114","doi-asserted-by":"publisher","DOI":"10.3892\/or.2021.8028","volume":"45","author":"E Tremante","year":"2021","unstructured":"Tremante E, Sibilio L, Centola F, Knutti N, Holzapfel G, Manni I, et al. Toolbox: Strep-tagged nano-assemblies of antibody-drug-conjugates (ADC) for modular and conditional cancer drugging. Oncol Rep. 2021;45(5):77.","journal-title":"Oncol Rep"},{"issue":"14","key":"1752_CR115","doi-asserted-by":"publisher","first-page":"12752","DOI":"10.1021\/acsomega.2c07949","volume":"8","author":"H Wu","year":"2023","unstructured":"Wu H, Ding X, Chen Y, Cai Y, Yang Z, Jin J. Constructed tumor-targeted and MMP-2 biocleavable antibody conjugated silica nanoparticles for efficient cancer therapy. ACS Omega. 2023;8(14):12752\u201360.","journal-title":"ACS Omega"},{"issue":"6","key":"1752_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061643","volume":"15","author":"V Lehot","year":"2023","unstructured":"Lehot V, Neuberg P, Ripoll M, Daubeuf F, Erb S, Dovgan I, et al. Targeted anticancer agent with original mode of action prepared by supramolecular assembly of antibody oligonucleotide conjugates and cationic nanoparticles. Pharmaceutics. 2023;15(6):1643.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1752_CR117","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3892\/ol.2016.4883","volume":"12","author":"YJ Chen","year":"2016","unstructured":"Chen YJ, Chen SY, Lovel R, Ku YC, Lai YH, Hung CL, et al. Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016;12(3):2107\u201314.","journal-title":"Oncol Lett"},{"issue":"3","key":"1752_CR118","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1742-7843.2010.00642.x","volume":"108","author":"Z Wu","year":"2011","unstructured":"Wu Z, Li X, Zeng Y, Zhuang X, Shen H, Zhu H, et al. In vitro and in vivo Inhibition of MRP gene expression and reversal of multidrug resistance by SiRNA. Basic Clin Pharmacol Toxicol. 2011;108(3):177\u201384.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1752_CR119","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.21037\/tcr-24-1129","volume":"13","author":"R Chen","year":"2024","unstructured":"Chen R, Yu Y, Liu R, Chen Q. Targeting breast cancer resistance protein (BCRP\/ABCG2) in cancer. Transl Cancer Res. 2024;13:6550\u201364.","journal-title":"Transl Cancer Res"},{"key":"1752_CR120","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/17425255.2019.1591373","volume":"15","author":"Z Safar","year":"2019","unstructured":"Safar Z, Kis E, Erdo F, Zolnerciks JK, Krajcsi P. ABCG2\/BCRP: variants, transporter interaction profile of substrates and inhibitors. Expert Opin Drug Metab Toxicol. 2019;15:313\u201328.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"18","key":"1752_CR121","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1158\/0008-5472.CAN-15-0030","volume":"75","author":"M Morfouace","year":"2015","unstructured":"Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, et al. ABCG2 transporter expression impacts group 3 medulloblastoma response to chemotherapy. Cancer Res. 2015;75(18):3879\u201389.","journal-title":"Cancer Res"},{"key":"1752_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2020.111963","volume":"210","author":"P M\u00fcller","year":"2020","unstructured":"M\u00fcller P, Abdel Gaber SA, Zimmermann W, Wittig R, Stepp H. ABCG2 influence on the efficiency of photodynamic therapy in glioblastoma cells. J Photochem Photobiol B. 2020;210:111963.","journal-title":"J Photochem Photobiol B"},{"key":"1752_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115666","volume":"259","author":"J Zhu","year":"2023","unstructured":"Zhu J, Lei S, Lu J, Hao Y, Qian Q, Devanathan AS, et al. Metabolism-guided development of Ko143 analogs as ABCG2 inhibitors. Eur J Med Chem. 2023;259:115666.","journal-title":"Eur J Med Chem"},{"key":"1752_CR124","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bbrc.2004.03.040","volume":"317","author":"HC Cooray","year":"2004","unstructured":"Cooray HC, Janvilisri T, van Veen HW, Hladky SB, Barrand MA. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun. 2004;317:269\u201375.","journal-title":"Biochem Biophys Res Commun"},{"key":"1752_CR125","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2174\/1389200215666140926153522","volume":"15","author":"Y Hu","year":"2014","unstructured":"Hu Y, Li C, Li H, Li M, Shu X. Resveratrol-mediated reversal of tumor multi-drug resistance. Curr Drug Metab. 2014;15:703\u201310.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"1752_CR126","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.apsb.2018.12.002","volume":"9","author":"X Li","year":"2019","unstructured":"Li X, Tian Y, Tu MJ, Ho PY, Batra N, Yu AM. Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression. Acta Pharm Sin B. 2019;9(3):639\u201347.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"1752_CR127","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ygyno.2015.11.034","volume":"141","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhao L, Xiao Q, Jiang L, He M, Bai X, et al. MiR-302a\/b\/c\/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol Oncol. 2016;141(3):592\u2013601.","journal-title":"Gynecol Oncol"},{"key":"1752_CR128","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1752_CR129","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119674","volume":"24","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, et al. Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. 2023;24(11):9674.","journal-title":"Int J Mol Sci"},{"key":"1752_CR130","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80:1019\u201325.","journal-title":"Drugs"},{"issue":"10","key":"1752_CR131","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates JT, Sun S, Leshchiner I, Thimmiah N, Martin EE, McLoughlin D, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab Govitecan in triple-negative breast cancer. Cancer Discov. 2021;11(10):2436\u201345.","journal-title":"Cancer Discov"},{"issue":"1","key":"1752_CR132","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2024023930","volume":"144","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, et al. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024;144(1):61\u201373.","journal-title":"Blood"},{"issue":"1","key":"1752_CR133","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/bjh.16949","volume":"191","author":"GL Ryland","year":"2020","unstructured":"Ryland GL, Barraclough A, Fong CY, Fleming S, Bajel A, Hofmann O, et al. Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia. Br J Haematol. 2020;191(1):123\u20136.","journal-title":"Br J Haematol"},{"key":"1752_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041278","volume":"15","author":"RO Abelman","year":"2023","unstructured":"Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of resistance to antibody-drug conjugates. Cancers (Basel). 2023;15:1278.","journal-title":"Cancers (Basel)"},{"key":"1752_CR135","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00277-022-05054-9","volume":"102","author":"HM Prince","year":"2023","unstructured":"Prince HM, Hutchings M, Domingo-Domenech E, Eichenauer DA, Advani R. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Ann Hematol. 2023;102:13\u201329.","journal-title":"Ann Hematol"},{"key":"1752_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24108731","volume":"24","author":"M Nakashima","year":"2023","unstructured":"Nakashima M, Uchimaru K. CD30 expression and its functions during the disease progression of adult T-cell leukemia\/lymphoma. Int J Mol Sci. 2023;24:8731.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"1752_CR137","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of Brentuximab Vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30(18):2183\u20139.","journal-title":"J Clin Oncol"},{"key":"1752_CR138","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1752_CR139","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14(6):1376\u201384.","journal-title":"Mol Cancer Ther"},{"key":"1752_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216024","volume":"554","author":"L Gandullo-S\u00e1nchez","year":"2023","unstructured":"Gandullo-S\u00e1nchez L, Pandiella A. An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Lett. 2023;554:216024.","journal-title":"Cancer Lett"},{"issue":"4","key":"1752_CR141","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","volume":"14","author":"F Loganzo","year":"2015","unstructured":"Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14(4):952\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"1752_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101792","volume":"5","author":"A Gupta","year":"2024","unstructured":"Gupta A, Michelini F, Shao H, Yeh C, Drago JZ, Liu D, et al. EGFR-directed antibodies promote HER2 ADC internalization and efficacy. Cell Rep Med. 2024;5(11):101792.","journal-title":"Cell Rep Med"},{"issue":"2","key":"1752_CR143","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1158\/1078-0432.CCR-13-0358","volume":"20","author":"GD Phillips","year":"2014","unstructured":"Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, et al. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res. 2014;20(2):456\u201368.","journal-title":"Clin Cancer Res"},{"key":"1752_CR144","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1752_CR145","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18(2):79\u201392.","journal-title":"Nat Rev Urol"},{"key":"1752_CR146","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s42255-023-00963-z","volume":"6","author":"M Demicco","year":"2024","unstructured":"Demicco M, Liu XZ, Leithner K, Fendt SM. Metabolic heterogeneity in cancer. Nat Metab. 2024;6:18\u201338.","journal-title":"Nat Metab"},{"issue":"5","key":"1752_CR147","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, Gharibvand RS, Eskandari N. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 2024;44(5):521\u201353.","journal-title":"Cancer Commun"},{"issue":"10","key":"1752_CR148","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116\u201335.","journal-title":"Cancer Discov"},{"key":"1752_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04124-6","volume":"12","author":"M Xie","year":"2021","unstructured":"Xie M, Fu XG, Jiang K. Notch1\/TAZ axis promotes aerobic Glycolysis and immune escape in lung cancer. Cell Death Dis. 2021;12:832.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1752_CR150","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cllc.2019.09.004","volume":"21","author":"H Xia","year":"2020","unstructured":"Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, et al. Evidence of NTRK1 fusion as resistance mechanism to EGFR TKI in EGFR\u2009+\u2009NSCLC: results from a large-scale survey of NTRK1 fusions in Chinese patients with lung cancer. Clin Lung Cancer. 2020;21(3):247\u201354.","journal-title":"Clin Lung Cancer"},{"key":"1752_CR151","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.trecan.2019.09.008","volume":"5","author":"VW Zhu","year":"2019","unstructured":"Zhu VW, Klempner SJ, Ou SI. Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer. Trends Cancer. 2019;5:677\u201392.","journal-title":"Trends Cancer"},{"issue":"17","key":"1752_CR152","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713077","volume":"24","author":"EM Urbanska","year":"2023","unstructured":"Urbanska EM, Grauslund M, Koffeldt PR, Truelsen SLB, L\u00f6fgren JO, Costa JC, et al. Real-world data on combined EGFR-TKI and crizotinib treatment for acquired and de novo MET amplification in patients with metastatic EGFR-mutated NSCLC. Int J Mol Sci. 2023;24(17):13077.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1752_CR153","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cllc.2024.07.012","volume":"25","author":"F Acker","year":"2024","unstructured":"Acker F, Klein A, Rasokat A, Eisert A, Kron A, Christopoulos P, et al. Multicenter Real-World analysis of combined MET and EGFR Inhibition in patients with Non-Small cell lung cancer and acquired MET amplification or polysomy after EGFR Inhibition. Clin Lung Cancer. 2024;25(8):672\u2013e6825.","journal-title":"Clin Lung Cancer"},{"key":"1752_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0900-z","volume":"19","author":"T Baldassarre","year":"2017","unstructured":"Baldassarre T, Truesdell P, Craig AW. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. Breast Cancer Res. 2017;19:110.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1752_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0900-z","volume":"19","author":"T Baldassarre","year":"2017","unstructured":"Baldassarre T, Truesdell P, Craig AW. Endophilin a2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. Breast Cancer Res. 2017;19(1):110.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1752_CR156","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","volume":"17","author":"M Sung","year":"2018","unstructured":"Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, et al. Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). Mol Cancer Ther. 2018;17(1):243\u201353.","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"1752_CR157","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1752_CR158","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2967\/jnumed.123.267110","volume":"65","author":"C Qi","year":"2024","unstructured":"Qi C, Guo R, Chen Y, Li C, Liu C, Zhang M, et al. 68Ga-NC-BCH whole-body PET imaging rapidly targets Claudin18.2 in lesions in gastrointestinal cancer patients. J Nucl Med. 2024;65(6):856\u201363.","journal-title":"J Nucl Med"},{"issue":"21","key":"1752_CR159","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1158\/0008-5472.CAN-23-4066","volume":"84","author":"YW Li","year":"2024","unstructured":"Li YW, Dai LJ, Wu XR, Zhao S, Xu YZ, Jin X, et al. Molecular characterization and classification of HER2-positive breast cancer inform tailored therapeutic strategies. Cancer Res. 2024;84(21):3669\u201383.","journal-title":"Cancer Res"},{"issue":"8","key":"1752_CR160","doi-asserted-by":"publisher","first-page":"oyae304","DOI":"10.1093\/oncolo\/oyae304","volume":"30","author":"K Wang","year":"2024","unstructured":"Wang K, Xu T, Wu J, Yuan Y, Guan X, Zhu C. Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis. Oncologist. 2025;30(8):oyae304. https:\/\/doi.org\/10.1093\/oncolo\/oyae304","journal-title":"Oncologist"},{"issue":"8","key":"1752_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06940-y","volume":"15","author":"M Izumi","year":"2024","unstructured":"Izumi M, Fujii M, Kobayashi IS, Ho V, Kashima Y, Udagawa H, et al. Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer. Cell Death Dis. 2024;15(8):580.","journal-title":"Cell Death Dis"},{"key":"1752_CR162","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","volume":"66","author":"M Goldstein","year":"2015","unstructured":"Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. 2015;66:129\u201343.","journal-title":"Annu Rev Med"},{"key":"1752_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2024.108078","volume":"171","author":"S Sun","year":"2024","unstructured":"Sun S, Wang K, Guo D, Zheng H, Liu Y, Shen H, et al. Identification of the key DNA damage response genes for predicting immunotherapy and chemotherapy efficacy in lung adenocarcinoma based on bulk, single-cell RNA sequencing, and spatial transcriptomics. Comput Biol Med. 2024;171:108078.","journal-title":"Comput Biol Med"},{"issue":"9","key":"1752_CR164","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358.","journal-title":"Nat Med"},{"issue":"2","key":"1752_CR165","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/2159-8290.CD-18-0598","volume":"9","author":"F Sanchez-Vega","year":"2019","unstructured":"Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, et al. EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer. Cancer Discov. 2019;9(2):199\u2013209.","journal-title":"Cancer Discov"},{"key":"1752_CR166","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.3390\/cancers15164145","volume":"5","author":"MC Su","year":"2023","unstructured":"Su MC, Nethi SK, Dhanyamraju PK, Prabha S. Nanomedicine strategies for targeting tumor stroma. Cancers (Basel). 2023;5:4145.","journal-title":"Cancers (Basel)"},{"key":"1752_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62470-9","author":"AM Arias-Lorza","year":"2023","unstructured":"Arias-Lorza AM, Costello JR, Hingorani SR, Von Hoff DD, Korn RL, Raghunand N. Tumor response to Stroma-Modifying therapy: magnetic resonance imaging findings in Early-Phase clinical trials of pegvorhyaluronidase alpha (PEGPH20). Res Sq [Preprint]. 2023. https:\/\/doi.org\/10.1038\/s41598-024-62470-9.","journal-title":"Res Sq [Preprint]"},{"key":"1752_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115812","volume":"24","author":"N Cirillo","year":"2023","unstructured":"Cirillo N. The Hyaluronan\/CD44 axis: a double-edged sword in cancer. Int J Mol Sci. 2023;24:15812.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1752_CR169","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","volume":"21","author":"PP Provenzano","year":"2012","unstructured":"Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418\u201329.","journal-title":"Cancer Cell"},{"issue":"1","key":"1752_CR170","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","volume":"62","author":"MA Jacobetz","year":"2013","unstructured":"Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112\u201320.","journal-title":"Gut"},{"issue":"1","key":"1752_CR171","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02701-z","volume":"19","author":"S Wang","year":"2021","unstructured":"Wang S, Bager CL, Karsdal MA, Chondros D, Taverna D, Willumsen N. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase Alfa. J Transl Med. 2021;19(1):39.","journal-title":"J Transl Med"},{"key":"1752_CR172","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1752_CR173","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cac2.12414","volume":"43","author":"JW Eun","year":"2023","unstructured":"Eun JW, Yoon JH, Ahn HR, Kim S, Kim YB, Lim SB, et al. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun. 2023;43(4):455\u201379.","journal-title":"Cancer Commun"},{"key":"1752_CR174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.matbio.2022.11.005","volume":"115","author":"Y Lu","year":"2023","unstructured":"Lu Y, Jin Z, Hou J, Wu X, Yu Z, Yao L, et al. Calponin 1 increases cancer-associated fibroblasts-mediated matrix stiffness to promote chemoresistance in gastric cancer. Matrix Biol. 2023;115:1\u201315.","journal-title":"Matrix Biol"},{"issue":"13","key":"1752_CR175","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-19-2238","volume":"26","author":"M Fabre","year":"2020","unstructured":"Fabre M, Ferrer C, Dom\u00ednguez-Hormaetxe S, Bockorny B, Murias L, Seifert O, et al. OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models. Clin Cancer Res. 2020;26(13):3420\u201330.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1752_CR176","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1158\/2767-9764.CRC-24-0248","volume":"4","author":"JP Gallant","year":"2024","unstructured":"Gallant JP, Hintz HM, Gunaratne GS, Breneman MT, Recchia EE, West JL, et al. Mechanistic characterization of cancer-associated fibroblast depletion via an antibody-drug conjugate targeting fibroblast activation protein. Cancer Res Commun. 2024;4(6):1481\u201394.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"1752_CR177","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","volume":"1","author":"DG DeNardo","year":"2011","unstructured":"DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54\u201367.","journal-title":"Cancer Discov"},{"issue":"3","key":"1752_CR178","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73(3):1128\u201341.","journal-title":"Cancer Res"},{"issue":"6","key":"1752_CR179","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ccell.2018.05.005","volume":"33","author":"JD Waight","year":"2018","unstructured":"Waight JD, Chand D, Dietrich S, Gombos R, Horn T, Gonzalez AM, et al. Selective Fc\u03b3R Co-engagement on apcs modulates the activity of therapeutic antibodies targeting T cell antigens. Cancer Cell. 2018;33(6):1033\u2013e10475.","journal-title":"Cancer Cell"},{"issue":"7","key":"1752_CR180","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-17-0019","volume":"16","author":"F Li","year":"2017","unstructured":"Li F, Ulrich M, Jonas M, Stone IJ, Linares G, Zhang X, et al. Tumor-associated macrophages can contribute to antitumor activity through Fc\u03b3R-mediated processing of antibody-drug conjugates. Mol Cancer Ther. 2017;16(7):1347\u201354.","journal-title":"Mol Cancer Ther"},{"key":"1752_CR181","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR, Yeager RL, Philip BK, Bawa B, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110\u201325.","journal-title":"Pharmacol Ther"},{"key":"1752_CR182","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","volume":"39","author":"M Aoyama","year":"2022","unstructured":"Aoyama M, Tada M, Yokoo H, Demizu Y, Ishii-Watabe A. Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates. Pharm Res. 2022;39:89\u2013103.","journal-title":"Pharm Res"},{"issue":"4","key":"1752_CR183","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1158\/1535-7163.MCT-18-0977","volume":"18","author":"F Li","year":"2019","unstructured":"Li F, Ulrich ML, Shih VF, Cochran JH, Hunter JH, Westendorf L, et al. Mouse strains influence clearance and efficacy of antibody and antibody-drug conjugate via Fc-Fc\u03b3R interaction. Mol Cancer Ther. 2019;18(4):780\u20137.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"1752_CR184","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1021\/acs.molpharmaceut.6b00995","volume":"14","author":"N Dimasi","year":"2017","unstructured":"Dimasi N, Fleming R, Zhong H, Bezabeh B, Kinneer K, Christie RJ, et al. Efficient preparation of site-specific antibody-drug conjugates using cysteine insertion. Mol Pharm. 2017;14(5):1501\u201316.","journal-title":"Mol Pharm"},{"issue":"10","key":"1752_CR185","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1535-7163.MCT-23-0701","volume":"23","author":"Q Guo","year":"2024","unstructured":"Guo Q, Gao B, Song R, Li W, Zhu S, Xie Q, et al. FZ-AD005, a novel DLL3-targeted antibody-drug conjugate with topoisomerase I inhibitor, shows potent antitumor activity in preclinical models. Mol Cancer Ther. 2024;23(10):1367\u201377.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1752_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.","journal-title":"Mol Cancer"},{"issue":"4","key":"1752_CR187","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/1541-7786.MCR-19-0856","volume":"18","author":"V Indira Chandran","year":"2020","unstructured":"Indira Chandran V, M\u00e5nsson AS, Barbachowska M, Cerezo-Maga\u00f1a M, Nodin B, Joshi B, et al. Hypoxia attenuates trastuzumab uptake and trastuzumab-Emtansine (T-DM1) cytotoxicity through redistribution of phosphorylated Caveolin-1. Mol Cancer Res. 2020;18(4):644\u201356.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1752_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-09009-7","volume":"21","author":"V Smith","year":"2021","unstructured":"Smith V, Mukherjee D, Lunj S, Choudhury A, Hoskin P, West C, et al. The effect of hypoxia on PD-L1 expression in bladder cancer. BMC Cancer. 2021;21(1):1271.","journal-title":"BMC Cancer"},{"issue":"1","key":"1752_CR189","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02229-6","volume":"41","author":"S Dong","year":"2022","unstructured":"Dong S, Liang S, Cheng Z, Zhang X, Luo L, Li L, et al. ROS\/PI3K\/Akt and Wnt\/\u03b2-catenin signalings activate HIF-1\u03b1-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. J Exp Clin Cancer Res. 2022;41(1):15.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"1752_CR190","doi-asserted-by":"publisher","first-page":"6933","DOI":"10.18632\/oncotarget.6903","volume":"7","author":"XY Dai","year":"2016","unstructured":"Dai XY, Zhuang LH, Wang DD, Zhou TY, Chang LL, Gai RH, et al. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells. Oncotarget. 2016;7(6):6933\u201347.","journal-title":"Oncotarget"},{"issue":"9","key":"1752_CR191","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156774","volume":"132","author":"S Salman","year":"2022","unstructured":"Salman S, Meyers DJ, Wicks EE, Lee SN, Datan E, Thomas AM, et al. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. J Clin Invest. 2022;132(9):e156774.","journal-title":"J Clin Invest"},{"issue":"1","key":"1752_CR192","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02724-y","volume":"42","author":"TW Kao","year":"2023","unstructured":"Kao TW, Bai GH, Wang TL, Shih IM, Chuang CM, Lo CL, et al. Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance. J Exp Clin Cancer Res. 2023;42(1):171.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"1752_CR193","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1172\/JCI96268","volume":"128","author":"P Jayaprakash","year":"2018","unstructured":"Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, et al. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J Clin Invest. 2018;128(11):5137\u201349.","journal-title":"J Clin Invest"},{"issue":"1","key":"1752_CR194","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00833-8","volume":"7","author":"Y Wang","year":"2022","unstructured":"Wang Y, Xiao D, Li J, Fan S, Xie F, Zhong W, et al. From prodrug to pro-prodrug: hypoxia-sensitive antibody-drug conjugates. Signal Transduct Target Ther. 2022;7(1):20.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1752_CR195","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/bjc.2012.559","volume":"108","author":"YC Shen","year":"2013","unstructured":"Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes Sorafenib resistance of hepatocellular carcinoma. Br J Cancer. 2013;108(1):72\u201381.","journal-title":"Br J Cancer"},{"issue":"19","key":"1752_CR196","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"5","key":"1752_CR197","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18(5):640\u201353.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1752_CR198","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321.","journal-title":"N Engl J Med"},{"issue":"7","key":"1752_CR199","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1752_CR200","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","volume":"25","author":"EF Smit","year":"2024","unstructured":"Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodr\u00edguez L, et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024;25(4):439\u201354.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1752_CR201","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1752_CR202","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746\u201356.","journal-title":"Ann Oncol"},{"issue":"4","key":"1752_CR203","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","volume":"24","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24(4):913\u201325.","journal-title":"Gastric Cancer"},{"issue":"11","key":"1752_CR204","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","volume":"41","author":"Z Peng","year":"2021","unstructured":"Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun. 2021;41(11):1173\u201382.","journal-title":"Cancer Commun"},{"issue":"1","key":"1752_CR205","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27(1):43\u201351.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1752_CR206","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Dur\u00e1n I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384(12):1125\u201335.","journal-title":"N Engl J Med"},{"issue":"8","key":"1752_CR207","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741\u201351.","journal-title":"N Engl J Med"},{"issue":"23","key":"1752_CR208","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garc\u00eda Y, Banerjee S, Lorusso D, et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162\u201374.","journal-title":"N Engl J Med"},{"key":"1752_CR209","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"M Myung-Ju Ahn","year":"2025","unstructured":"Myung-Ju Ahn M, Kentaro Tanaka M, Luis Paz-Ares M, Robin Cornelissen M, Nicolas Girard M, Pons-Tostivint ME, et al. Datopotamab Deruxtecan versus docetaxel for previously treated advanced or metastatic Non-Small cell lung cancer: the Randomized, Open-Label phase III TROPION-Lung01 study. J Clin Oncol. 2025;43:260\u201372.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1752_CR210","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","volume":"42","author":"LG Paz-Ares","year":"2024","unstructured":"Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III evoke-01 study. J Clin Oncol. 2024;42(24):2860\u201372.","journal-title":"J Clin Oncol"},{"issue":"10390","key":"1752_CR211","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773\u201385.","journal-title":"Lancet"},{"issue":"1","key":"1752_CR212","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9\u201320.","journal-title":"N Engl J Med"},{"issue":"25","key":"1752_CR213","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"1752_CR214","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.22.00575","volume":"41","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in anti-Human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. 2023;41(4):816\u201325.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1752_CR215","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/sj.leu.2403901","volume":"19","author":"S Amadori","year":"2005","unstructured":"Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European organisation for research and treatment of cancer and gruppo Italiano malattie ematologiche dell\u2019adulto leukemia groups. Leukemia. 2005;19(10):1768\u201373.","journal-title":"Leukemia"},{"issue":"12","key":"1752_CR216","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","volume":"30","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med. 2024;30(12):3717\u201327.","journal-title":"Nat Med"},{"issue":"6","key":"1752_CR217","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179501","volume":"12","author":"C Siebenk\u00e4s","year":"2017","unstructured":"Siebenk\u00e4s C, Chiappinelli KB, Guzzetta AA, Sharma A, Jeschke J, Vatapalli R, et al. Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLoS ONE. 2017;12(6):e0179501.","journal-title":"PLoS ONE"},{"issue":"1","key":"1752_CR218","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03843-6","volume":"5","author":"TS Rodems","year":"2022","unstructured":"Rodems TS, Heninger E, Stahlfeld CN, Gilsdorf CS, Carlson KN, Kircher MR, et al. Reversible epigenetic alterations regulate class I HLA loss in prostate cancer. Commun Biol. 2022;5(1):897.","journal-title":"Commun Biol"},{"key":"1752_CR219","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrd2180","volume":"5","author":"SD Gore","year":"2006","unstructured":"Gore SD, Jones C, Kirkpatrick P, Decitabine. Nat Rev Drug Discov. 2006;5:891\u20132.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"1752_CR220","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/neuonc\/noac107","volume":"24","author":"R Ma","year":"2022","unstructured":"Ma R, Rei M, Woodhouse I, Ferris K, Kirschner S, Chandran A, et al. Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma. Neuro Oncol. 2022;24(12):2093\u2013106.","journal-title":"Neuro Oncol"},{"key":"1752_CR221","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101086","volume":"59","author":"A Fehn","year":"2025","unstructured":"Fehn A, von Witzleben A, Grages A, Kors TA, Ezi\u0107 J, Betzler AC, et al. 5-Aza-2\u2019-deoxycytidin (Decitabine) increases cancer-testis antigen expression in head and neck squamous cell carcinoma and modifies immune checkpoint expression, especially in CD39-positive CD8 and CD4 T cells. Neoplasia. 2025;59:101086.","journal-title":"Neoplasia"},{"issue":"30","key":"1752_CR222","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400203","volume":"11","author":"P Zhang","year":"2024","unstructured":"Zhang P, Tao C, Lu Y, Li P, Wang X, Dai Y, et al. Epigenetic reprogramming potentiates ICAM1 antibody drug conjugates in preclinical models of melanoma. Adv Sci. 2024;11(30):e2400203.","journal-title":"Adv Sci"},{"issue":"1","key":"1752_CR223","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00573-8","volume":"9","author":"M Zhao","year":"2023","unstructured":"Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, et al. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab Govitecan. NPJ Breast Cancer. 2023;9(1):66.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"1752_CR224","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04073-y","volume":"21","author":"N Taib","year":"2023","unstructured":"Taib N, Merhi M, Inchakalody V, Mestiri S, Hydrose S, Makni-Maalej K, et al. Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy. J Transl Med. 2023;21(1):235.","journal-title":"J Transl Med"},{"issue":"1","key":"1752_CR225","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01626-x","volume":"8","author":"Y Fang","year":"2023","unstructured":"Fang Y, Zhang MC, He Y, Li C, Fang H, Xu PP, et al. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):381.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"1752_CR226","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165673","volume":"133","author":"X Li","year":"2023","unstructured":"Li X, Li Y, Dong L, Chang Y, Zhang X, Wang C, et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8\u2009+\u2009progenitor exhausted T cell expansion in tumor models. J Clin Invest. 2023;133(7):e165673.","journal-title":"J Clin Invest"},{"issue":"2","key":"1752_CR227","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010294","volume":"13","author":"HD Bear","year":"2025","unstructured":"Bear HD, Deng X, Bandyopadhyay D, Idowu M, Jenkins TM, Kmieciak M, et al. T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy. J Immunother Cancer. 2025;13(2):e010294.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1752_CR228","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003392","volume":"10","author":"M Goswami","year":"2022","unstructured":"Goswami M, Gui G, Dillon LW, Lindblad KE, Thompson J, Valdez J, et al. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. J Immunother Cancer. 2022;10(1):e003392.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1752_CR229","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002347","volume":"9","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wang C, Li X, Dong L, Yang Q, Chen M, et al. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory hodgkin lymphoma. J Immunother Cancer. 2021;9(4):e002347.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1752_CR230","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010355","volume":"12","author":"J Wang","year":"2024","unstructured":"Wang J, Li S, Jiang H, Chang YJ, Zhao X, Jia J, et al. Sintilimab plus decitabine for higher-risk treatment-na\u00efve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial. J Immunother Cancer. 2024;12(11):e010355.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1752_CR231","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","volume":"11","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2024;11(1):e38\u201350.","journal-title":"Lancet Haematol"},{"issue":"15","key":"1752_CR232","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1182\/blood.2022017686","volume":"141","author":"JS Garcia","year":"2023","unstructured":"Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, et al. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-na\u00efve settings. Blood. 2023;141(15):1884\u20138.","journal-title":"Blood"},{"issue":"1","key":"1752_CR233","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35059-x","volume":"13","author":"A Verma","year":"2022","unstructured":"Verma A, Singh A, Singh MP, Nengroo MA, Saini KK, Satrusal SR, et al. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis. Nat Commun. 2022;13(1):7344.","journal-title":"Nat Commun"},{"key":"1752_CR234","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/1078-0432.CCR-19-1351","volume":"26","author":"L Zhou","year":"2020","unstructured":"Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer. Clin Cancer Res. 2020;26:290\u2013300.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"1752_CR235","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1182\/bloodadvances.2021006069","volume":"6","author":"CM Bourne","year":"2022","unstructured":"Bourne CM, Mun SS, Dao T, Aretz ZEH, Molvi Z, Gejman RS, et al. Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment. Blood Adv. 2022;6(14):4107\u201321.","journal-title":"Blood Adv"},{"issue":"3","key":"1752_CR236","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","volume":"43","author":"P Porazzi","year":"2025","unstructured":"Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al. EZH1\/EZH2 Inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell. 2025;43(3):537\u2013e5517.","journal-title":"Cancer Cell"},{"key":"1752_CR237","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162907","volume":"8","author":"E Sayar","year":"2023","unstructured":"Sayar E, et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI Insight. 2023;8:e162907.","journal-title":"JCI Insight"},{"issue":"1","key":"1752_CR238","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2210-0","volume":"11","author":"XW Guan","year":"2020","unstructured":"Guan XW, Wang HQ, Ban WW, Chang Z, Chen HZ, Jia L, et al. Novel HDAC inhibitor Chidamide synergizes with rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis. 2020;11(1):20.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1752_CR239","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02598-5","volume":"20","author":"P Zhang","year":"2022","unstructured":"Zhang P, Du Y, Bai H, Wang Z, Duan J, Wang X, et al. Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Med. 2022;20(1):435.","journal-title":"BMC Med"},{"key":"1752_CR240","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114528","volume":"154","author":"Y Jia","year":"2025","unstructured":"Jia Y, Li J, Mei W, Zhang H, Wang Z, Xie X, et al. Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation. Int Immunopharmacol. 2025;154:114528.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"1752_CR241","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00262-017-2091-y","volume":"67","author":"D Briere","year":"2018","unstructured":"Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, et al. The class I\/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol Immunother. 2018;67(3):381\u201392.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1752_CR242","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1111\/bjh.19658","volume":"205","author":"F Spriano","year":"2024","unstructured":"Spriano F, Tarantelli C, Cascione L, Gaudio E, Golino G, Scalise L, et al. Targeting CD25\u2009+\u2009lymphoma cells with the antibody-drug conjugate camidanlumab Tesirine as a single agent or in combination with targeted agents. Br J Haematol. 2024;205(5):1873\u201382.","journal-title":"Br J Haematol"},{"issue":"1","key":"1752_CR243","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3324\/haematol.2013.096545","volume":"99","author":"RB Walter","year":"2014","unstructured":"Walter RB, Medeiros BC, Gardner KM, Orlowski KF, Gallegos L, Scott BL, et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I\/II study. Haematologica. 2014;99(1):54\u20139.","journal-title":"Haematologica"},{"key":"1752_CR244","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106984","volume":"123","author":"SM Abedin","year":"2022","unstructured":"Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, et al. Safety and efficacy of pracinostat in combination with Gemtuzumab Ozogamicin (PraGO) in patients with relapsed\/refractory acute myeloid leukemia. Leuk Res. 2022;123:106984.","journal-title":"Leuk Res"},{"issue":"1","key":"1752_CR245","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01517-9","volume":"21","author":"ZD Shi","year":"2022","unstructured":"Shi ZD, Hao L, Han XX, Wu ZX, Pang K, Dong Y, et al. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer. Mol Cancer. 2022;21(1):37.","journal-title":"Mol Cancer"},{"issue":"6166","key":"1752_CR246","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelson T, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84\u20137.","journal-title":"Science"},{"issue":"7","key":"1752_CR247","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/1535-7163.MCT-20-0708","volume":"20","author":"Q Sheng","year":"2021","unstructured":"Sheng Q, D\u2019Alessio JA, Menezes DL, Karim C, Tang Y, Tam A, et al. PCA062, a P-cadherin targeting Antibody-Drug Conjugate, displays potent antitumor activity against P-cadherin-expressing malignancies. Mol Cancer Ther. 2021;20(7):1270\u201382.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1752_CR248","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02000-1","volume":"27","author":"BA Lipert","year":"2025","unstructured":"Lipert BA, Siemens KN, Khan A, Airey R, Dam GH, Lu M, et al. CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance. Breast Cancer Res. 2025;27(1):48.","journal-title":"Breast Cancer Res"},{"issue":"7408","key":"1752_CR249","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature11249","volume":"487","author":"TR Wilson","year":"2012","unstructured":"Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487(7408):505\u20139.","journal-title":"Nature"},{"issue":"7126","key":"1752_CR250","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","volume":"445","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445(7126):437\u201341.","journal-title":"Nature"},{"issue":"12","key":"1752_CR251","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.1016140108","volume":"108","author":"JT Garrett","year":"2011","unstructured":"Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, S\u00e1nchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A. 2011;108(12):5021\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1752_CR252","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s10637-018-0593-x","volume":"36","author":"AHM de Vries Schultink","year":"2018","unstructured":"de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, et al. Translational PK-PD modeling analysis of MCLA-128, a HER2\/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose. Invest New Drugs. 2018;36(6):1006\u201315.","journal-title":"Invest New Drugs"},{"issue":"5","key":"1752_CR253","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","volume":"12","author":"AM Schram","year":"2022","unstructured":"Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. Cancer Discov. 2022;12(5):1233\u201347.","journal-title":"Cancer Discov"},{"issue":"6","key":"1752_CR254","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","volume":"392","author":"AM Schram","year":"2025","unstructured":"Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O\u2019Reilly EM, et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med. 2025;392(6):566\u201376.","journal-title":"N Engl J Med"},{"issue":"8","key":"1752_CR255","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41401-024-01279-8","volume":"45","author":"HF Zong","year":"2024","unstructured":"Zong HF, Li X, Han L, Wang L, Liu JJ, Yue YL, et al. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Acta Pharmacol Sin. 2024;45(8):1727\u201339.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"1752_CR256","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/1078-0432.CCR-22-2180","volume":"29","author":"SY Oh","year":"2023","unstructured":"Oh SY, Lee YW, Lee EJ, Kim JH, Park Y, Heo SG, et al. Preclinical study of a biparatopic METxMET antibody-drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC. Clin Cancer Res. 2023;29(1):221\u201332.","journal-title":"Clin Cancer Res"},{"key":"1752_CR257","doi-asserted-by":"crossref","unstructured":"Ab O, Bartle LM, Lanieri L, Ponte JF, Westin EH. IMGN151 - a next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression. Cancer Res. 2020; 80, abstr. 2890.","DOI":"10.1158\/1538-7445.AM2020-2890"},{"issue":"3","key":"1752_CR258","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10549-009-0592-x","volume":"122","author":"R Dua","year":"2010","unstructured":"Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat. 2010;122(3):685\u201397.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"1752_CR259","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1634\/theoncologist.2018-0785","volume":"24","author":"A Sartore-Bianchi","year":"2019","unstructured":"Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist. 2019;24(10):1395\u2013402.","journal-title":"Oncologist"},{"issue":"2","key":"1752_CR260","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10637-025-01507-w","volume":"43","author":"H Huang","year":"2025","unstructured":"Huang H, Zhou Y, Shang C, Zhang Y, Shen Y. A novel anti-HER2\/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs. Invest New Drugs. 2025;43(2):262\u201375.","journal-title":"Invest New Drugs"},{"issue":"6\u2013Sup","key":"1752_CR261","first-page":"5","volume":"84","author":"W Wan","year":"2024","unstructured":"Wan W, Zhao S, Zhuo S, Zhang Y, Chen L, Li R, et al. Abstract 3139: BL-M11D1, a novel CD33-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation. Cancer Res. 2024;84(6\u2013Sup):5.","journal-title":"Cancer Res"},{"issue":"7","key":"1752_CR262","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25(7):901\u201311.","journal-title":"Lancet Oncol"},{"key":"1752_CR263","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.1158\/1538-7445.AM2023-5737","volume":"8","author":"Y Lara McGrath","year":"2023","unstructured":"Lara McGrath Y, Zheng S, Christ CC, Sachs S, Khelifa C, Windm\u00fcller, et al. Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR\/c-MET targeted bispecific antibody drug conjugate. Cancer Res. 2023;8:5737.","journal-title":"Cancer Res"},{"issue":"10","key":"1752_CR264","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009710","volume":"12","author":"Y Dong","year":"2024","unstructured":"Dong Y, Zhang Z, Luan S, Zheng M, Wang Z, Chen Y, et al. Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. J Immunother Cancer. 2024;12(10):e009710.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1752_CR265","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41401-024-01458-7","volume":"46","author":"M Wang","year":"2025","unstructured":"Wang M, Ma Q, Suthe SR, Hudson RE, Pan JY, Mikelis C, et al. Humanized dual-targeting antibody-drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity. Acta Pharmacol Sin. 2025;46(5):1375\u201389.","journal-title":"Acta Pharmacol Sin"},{"key":"1752_CR266","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ddtec.2018.08.005","volume":"30","author":"A Pahl","year":"2018","unstructured":"Pahl A, Lutz C, Hechler T. Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol. 2018;30:85\u20139.","journal-title":"Drug Discov Today Technol"},{"issue":"8","key":"1752_CR267","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jnci\/djs140","volume":"104","author":"G Moldenhauer","year":"2012","unstructured":"Moldenhauer G, Salnikov AV, L\u00fcttgau S, Herr I, Anderl J, Faulstich H. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst. 2012;104(8):622\u201334.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1752_CR268","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","volume":"20","author":"V Figueroa-Vazquez","year":"2021","unstructured":"Figueroa-Vazquez V, Ko J, Breunig C, Baumann A, Giesen N, P\u00e1lfi A, et al. HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers Amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2021;20(2):367\u201378.","journal-title":"Mol Cancer Ther"},{"key":"1752_CR269","unstructured":"Raab MS, Orlowski R, Richard S, Sebastian Grosicki MD, Istvan Takacs MD, Andras Strassz MD et al. HDP-101-01: first-in-human, phase 1 A clinical trial for relapsed\/refractory multiple myeloma patients: interim results. Presented at the 21st Annual International Myeloma Society Meeting and Exposition. 2024;abstr. OA-60."},{"key":"1752_CR270","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3843028\/v1","author":"RK Singh","year":"2024","unstructured":"Singh RK, Jones RJ, Shirazi F, Qin L, Zou J, Hong S, et al. Novel Anti-B-cell maturation antigen Alpha-Amanitin Antibody-drug conjugate HDP-101 shows superior activity to Belantamab Mafodotin and enhanced efficacy in deletion 17p myeloma models. Res Sq. 2024. https:\/\/doi.org\/10.21203\/rs.3.rs-3843028\/v1.","journal-title":"Res Sq"},{"issue":"4","key":"1752_CR271","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1158\/1535-7163.MCT-24-0266","volume":"24","author":"E Papacharisi","year":"2025","unstructured":"Papacharisi E, Braun AC, Vranic M, Pahl AM, Hechler T. Novel amanitin-based antibody-drug conjugates targeting TROP2 for the treatment of pancreatic cancer. Mol Cancer Ther. 2025;24(4):485\u201396.","journal-title":"Mol Cancer Ther"},{"key":"1752_CR272","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100728","volume":"53","author":"R Sciarrillo","year":"2020","unstructured":"Sciarrillo R, Wojtuszkiewicz A, Assaraf YG, Jansen G, Kaspers GJL, Giovannetti E, et al. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resist Updat. 2020;53:100728.","journal-title":"Drug Resist Updat"},{"issue":"4","key":"1752_CR273","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1021\/np300913h","volume":"76","author":"X Liu","year":"2013","unstructured":"Liu X, Biswas S, Berg MG, Antapli CM, Xie F, Wang Q, et al. Genomics-guided discovery of Thailanstatins A, B, and C as pre-mRNA splicing inhibitors and antiproliferative agents from burkholderia thailandensis MSMB43. J Nat Prod. 2013;76(4):685\u201393.","journal-title":"J Nat Prod"},{"issue":"8","key":"1752_CR274","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1021\/acs.bioconjchem.6b00291","volume":"27","author":"S Puthenveetil","year":"2016","unstructured":"Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, et al. Natural product splicing inhibitors: a new class of Antibody-Drug conjugate (ADC) payloads. Bioconjug Chem. 2016;27(8):1880\u20138.","journal-title":"Bioconjug Chem"},{"key":"1752_CR275","doi-asserted-by":"crossref","unstructured":"Anthony W, Tolcher BA, Carneiro YK, Chae JA, Villella et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: Dose escalation results. J Clin oncol. 2021;39;3015\u20133015.","DOI":"10.1200\/JCO.2021.39.15_suppl.3015"},{"issue":"1","key":"1752_CR276","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54138-9","volume":"15","author":"EG Fernandez","year":"2024","unstructured":"Fernandez EG, Mai WX, Song K, Bayley NA, Kim J, Zhu H, et al. Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma. Nat Commun. 2024;15(1):10089.","journal-title":"Nat Commun"},{"issue":"1","key":"1752_CR277","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021;12(1):3528.","journal-title":"Nat Commun"},{"key":"1752_CR278","doi-asserted-by":"publisher","first-page":"abstr2114","DOI":"10.1158\/1538-7445.AM2024-2114","volume":"84","author":"M Lina Wang","year":"2024","unstructured":"Lina Wang M, Xiong X, Gao C, Zhou Y, Han Y, Li, et al. Enhancing therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: a HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor. Cancer Res. 2024;84:abstr2114.","journal-title":"Cancer Res"},{"issue":"4","key":"1752_CR279","first-page":"71","volume":"2","author":"N Nilchan","year":"2019","unstructured":"Nilchan N, Li X, Pedzisa L, Nanna AR, Roush WR, Rader C. Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine\/cysteine conjugation. Antib Ther. 2019;2(4):71\u20138.","journal-title":"Antib Ther"},{"issue":"23\u201324","key":"1752_CR280","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1016\/j.bmcl.2018.10.043","volume":"28","author":"A Kumar","year":"2018","unstructured":"Kumar A, Kinneer K, Masterson L, Ezeadi E, Howard P, Wu H, et al. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads. Bioorg Med Chem Lett. 2018;28(23\u201324):3617\u201321.","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"1752_CR281","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2498162","volume":"17","author":"M Wen","year":"2025","unstructured":"Wen M, Yu A, Park Y, Calarese D, Gerber HP, Yin G. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations. MAbs. 2025;17(1):2498162.","journal-title":"MAbs"},{"key":"1752_CR282","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15674-1","volume":"7","author":"MP Johansson","year":"2017","unstructured":"Johansson MP, Maaheimo H, Ekholm FS. New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling. Sci Rep. 2017;7:15920.","journal-title":"Sci Rep"},{"key":"1752_CR283","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101713","volume":"66","author":"JM Blander","year":"2023","unstructured":"Blander JM. Different routes of MHC-I delivery to phagosomes and their consequences to CD8 T cell immunity. Semin Immunol. 2023;66:101713.","journal-title":"Semin Immunol"},{"key":"1752_CR284","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.847835","volume":"9","author":"J Yu","year":"2022","unstructured":"Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front Mol Biosci. 2022;9:847835.","journal-title":"Front Mol Biosci"},{"issue":"21","key":"1752_CR285","doi-asserted-by":"publisher","first-page":"15716","DOI":"10.1021\/acs.jmedchem.1c00961","volume":"64","author":"L He","year":"2021","unstructured":"He L, Wang L, Wang Z, Li T, Chen H, Zhang Y, et al. Immune modulating antibody-drug conjugate (IM-ADC) for cancer immunotherapy. J Med Chem. 2021;64(21):15716\u201326.","journal-title":"J Med Chem"},{"issue":"9","key":"1752_CR286","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-24-2449","volume":"31","author":"RA Bukhalid","year":"2025","unstructured":"Bukhalid RA, Duvall JR, Lancaster K, Catcott KC, Malli Cetinbas N, Monnell T, et al. XMT-2056, a HER2-directed STING agonist antibody-drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells. Clin Cancer Res. 2025;31(9):1766\u201382.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1752_CR287","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1158\/1535-7163.MCT-16-0364","volume":"15","author":"BE de Goeij","year":"2016","unstructured":"de Goeij BE, Vink T, Ten Napel H, Breij EC, Satijn D, Wubbolts R, et al. Efficient payload delivery by a bispecific Antibody-Drug conjugate targeting HER2 and CD63. Mol Cancer Ther. 2016;15(11):2688\u201397.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"1752_CR288","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216056","volume":"24","author":"W Zhuang","year":"2023","unstructured":"Zhuang W, Zhang W, Wang L, Xie L, Feng J, Zhang B, et al. Generation of a novel SORT1\u00d7HER2 bispecific antibody-drug conjugate targeting HER2-Low-Expression tumor. Int J Mol Sci. 2023;24(22):16056.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1752_CR289","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1158\/1535-7163.MCT-24-0319","volume":"24","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zheng M, Li M, Lu H, Liu N, Chen Y, et al. Development and characterization of a lysosome-targeting SLC3A2\/PD-L1 bispecific antibody-drug conjugate for enhanced antitumor efficacy in solid tumors. Mol Cancer Ther. 2025;24(2):261\u201374.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1752_CR290","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1124\/dmd.119.086595","volume":"47","author":"Y Ma","year":"2019","unstructured":"Ma Y, Dela Cruz-Chuh J, Khojasteh SC, Dragovich PS, Pillow TH, Zhang D. Carfilzomib is not an appropriate payload of antibody-drug conjugates due to rapid inactivation by lysosomal enzymes. Drug Metab Dispos. 2019;47(8):884\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1752_CR291","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","volume":"21","author":"SO Doronina","year":"2003","unstructured":"Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778\u201384.","journal-title":"Nat Biotechnol"},{"key":"1752_CR292","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/DDDT.S135571","volume":"11","author":"M Kalim","year":"2017","unstructured":"Kalim M, Chen J, Wang S, Lin C, Ullah S, Liang K, et al. Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates. Drug Des Devel Ther. 2017;11:2265\u201376.","journal-title":"Drug Des Devel Ther"},{"key":"1752_CR293","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1039\/C9BM01813A","volume":"8","author":"AC Del Valle","year":"2020","unstructured":"Del Valle AC, Su CK, Sun YC, Huang YF. NIR-cleavable drug adducts of gold nanostars for overcoming multidrug-resistant tumors. Biomater Sci. 2020;8:1934\u201350.","journal-title":"Biomater Sci"},{"key":"1752_CR294","doi-asserted-by":"publisher","first-page":"8265","DOI":"10.1021\/acs.analchem.1c01104","volume":"93","author":"E Thankarajan","year":"2021","unstructured":"Thankarajan E, Jadhav S, Luboshits G, Gellerman G, Patsenker L. Quantification of drug release degree in vivo using antibody-guided, dual-NIR-dye ratiometric system. Anal Chem. 2021;93:8265\u201372.","journal-title":"Anal Chem"},{"issue":"8","key":"1752_CR295","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.1021\/acsabm.1c00569","volume":"4","author":"N Zhang","year":"2021","unstructured":"Zhang N, Wang D, Jing X, Yang T, Yang H, Meng L. pH\/ROS dual-responsive polymer-drug-based nanocarriers: click-reaction preparation and fluorescence imaging-guided chemotherapy and photodynamic therapy. ACS Appl Bio Mater. 2021;4(8):6294\u2013303.","journal-title":"ACS Appl Bio Mater"},{"issue":"23","key":"1752_CR296","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314925","volume":"23","author":"WJ Zhang","year":"2022","unstructured":"Zhang WJ, Li S, Yan YZ, Park SS, Mohan A, Chung I, et al. Dual (pH- and ROS-) responsive antibacterial MXene-based nanocarrier for drug delivery. Int J Mol Sci. 2022;23(23):14925.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1752_CR297","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071827","volume":"15","author":"P Yao","year":"2023","unstructured":"Yao P, Wang X, Wang Q, Dai Q, Peng Y, Yuan Q, et al. Cyclic RGD-functionalized pH\/ROS dual-responsive nanoparticle for targeted breast cancer therapy. Pharmaceutics. 2023;15(7):1827.","journal-title":"Pharmaceutics"},{"issue":"5","key":"1752_CR298","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1021\/acs.biomac.2c01404","volume":"24","author":"X Wang","year":"2023","unstructured":"Wang X, Yang Y, Zhang G, Tang CY, Law WC, Yu C, et al. NIR-cleavable and pH-responsive polymeric yolk-shell nanoparticles for controlled drug release. Biomacromolecules. 2023;24(5):2009\u201321.","journal-title":"Biomacromolecules"},{"key":"1752_CR299","doi-asserted-by":"crossref","unstructured":"Menrad A, Menssen HD, editors. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets. 2005;9:491\u2013500.","DOI":"10.1517\/14728222.9.3.491"},{"issue":"9","key":"1752_CR300","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","volume":"21","author":"AT Hooper","year":"2022","unstructured":"Hooper AT, Marquette K, Chang CB, Golas J, Jain S, Lam MH, et al. Anti-Extra domain B splice variant of fibronectin Antibody-Drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint Blockade. Mol Cancer Ther. 2022;21(9):1462\u201372.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"1752_CR301","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1158\/1535-7163.MCT-21-0335","volume":"20","author":"S Tsujii","year":"2021","unstructured":"Tsujii S, Serada S, Fujimoto M, Uemura S, Namikawa T, Nomura T, et al. Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody-drug conjugates in pancreatic cancer. Mol Cancer Ther. 2021;20(12):2495\u2013505.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1752_CR302","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02249-0","volume":"10","author":"C Lee","year":"2025","unstructured":"Lee C, Kim MJ, Kumar A, Lee HW, Yang Y, Kim Y. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. Signal Transduct Target Ther. 2025;10(1):170.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1752_CR303","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","volume":"165","author":"T Inai","year":"2004","unstructured":"Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165(1):35\u201352.","journal-title":"Am J Pathol"},{"key":"1752_CR304","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118023","volume":"186","author":"H Mahaki","year":"2025","unstructured":"Mahaki H, Nobari S, Tanzadehpanah H, Babaeizad A, Kazemzadeh G, Mehrabzadeh M, et al. Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: therapeutic strategies and insights. Biomed Pharmacother. 2025;186:118023.","journal-title":"Biomed Pharmacother"},{"key":"1752_CR305","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106575","volume":"137","author":"Y Li","year":"2023","unstructured":"Li Y, Si R, Wang J, Hai P, Zheng Y, Zhang Q, et al. Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg Chem. 2023;137:106575.","journal-title":"Bioorg Chem"},{"key":"1752_CR306","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1042\/BST20180334","volume":"47","author":"MZ Johan","year":"2019","unstructured":"Johan MZ, Samuel MS. Rho-ROCK signaling regulates tumor-microenvironment interactions. Biochem Soc Trans. 2019;47:101\u20138.","journal-title":"Biochem Soc Trans"},{"key":"1752_CR307","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-030-35582-1_6","volume":"1223","author":"S Porazinski","year":"2020","unstructured":"Porazinski S, Parkin A, Pajic M. Rho-ROCK signaling in normal physiology and as a key player in shaping the tumor microenvironment. Adv Exp Med Biol. 2020;1223:99\u2013127.","journal-title":"Adv Exp Med Biol"},{"key":"1752_CR308","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.trecan.2022.12.001","volume":"9","author":"J Barcelo","year":"2023","unstructured":"Barcelo J, Samain R, Sanz-Moreno V. Preclinical to clinical utility of ROCK inhibitors in cancer. Trends Cancer. 2023;9:250\u201363.","journal-title":"Trends Cancer"},{"issue":"12","key":"1752_CR309","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.21873\/anticanres.11227","volume":"36","author":"H Takeda","year":"2016","unstructured":"Takeda H, Okada M, Suzuki S, Kuramoto K, Sakaki H, Watarai H, et al. Rho-associated protein kinase (ROCK) inhibitors inhibit survivin expression and sensitize pancreatic cancer stem cells to gemcitabine. Anticancer Res. 2016;36(12):6311\u20138.","journal-title":"Anticancer Res"},{"issue":"384","key":"1752_CR310","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai8504","volume":"9","author":"C Vennin","year":"2017","unstructured":"Vennin C, Chin VT, Warren SC, Lucas MC, Herrmann D, Magenau A, et al. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Sci Transl Med. 2017;9(384):eaai8504.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1752_CR311","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0251-9","volume":"9","author":"X Zhang","year":"2018","unstructured":"Zhang X, Liu X, Zhou W, Yang M, Ding Y, Wang Q, et al. Fasudil increases Temozolomide sensitivity and suppresses Temozolomide-resistant glioma growth via inhibiting ROCK2\/ABCG2. Cell Death Dis. 2018;9(2):190.","journal-title":"Cell Death Dis"},{"key":"1752_CR312","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jconrel.2024.03.041","volume":"369","author":"HY Tanaka","year":"2024","unstructured":"Tanaka HY, Nakazawa T, Miyazaki T, Cabral H, Masamune A, Kano MR. Targeting ROCK2 improves macromolecular permeability in a 3D fibrotic pancreatic cancer microenvironment model. J Control Release. 2024;369:283\u201395.","journal-title":"J Control Release"},{"issue":"1","key":"1752_CR313","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2021","unstructured":"Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2(1):18\u201333.","journal-title":"Nat Cancer"},{"issue":"9","key":"1752_CR314","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1021\/acs.molpharmaceut.2c00392","volume":"19","author":"S Fang","year":"2022","unstructured":"Fang S, Brems BM, Olawode EO, Miller JT, Brooks TA, Tumey LN. Design and characterization of immune-stimulating Imidazo[4,5-c]quinoline antibody-drug conjugates. Mol Pharm. 2022;19(9):3228\u201341.","journal-title":"Mol Pharm"},{"key":"1752_CR315","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282831","volume":"18","author":"D Corogeanu","year":"2023","unstructured":"Corogeanu D, Zaki K, Beavil AJ, Arnold JN, Diebold SS. Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue. PLoS ONE. 2023;18:e0282831.","journal-title":"PLoS ONE"},{"issue":"3","key":"1752_CR316","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1021\/acs.bioconjchem.4c00534","volume":"36","author":"E Sega","year":"2025","unstructured":"Sega E, Kotapati S, Poudel YB, Cheng Q, Sadanala K, Schneider B, et al. Targeted delivery of TLR7 agonists to the tumor microenvironment enhances tumor immunity via activation of tumor-resident myeloid cells. Bioconjug Chem. 2025;36(3):437\u201348.","journal-title":"Bioconjug Chem"},{"issue":"12","key":"1752_CR317","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","volume":"10","author":"F Janku","year":"2022","unstructured":"Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, et al. Preclinical characterization and phase I study of an Anti-HER2-TLR7 immune-stimulator antibody conjugate in patients with HER2\u2009+\u2009malignancies. Cancer Immunol Res. 2022;10(12):1441\u201361.","journal-title":"Cancer Immunol Res"},{"key":"1752_CR318","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1084\/jem.193.7.855","volume":"193","author":"PA Oldenborg","year":"2001","unstructured":"Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med. 2001;193:855\u201362.","journal-title":"J Exp Med"},{"issue":"8","key":"1752_CR319","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080882","volume":"9","author":"Y Si","year":"2021","unstructured":"Si Y, Zhang Y, Guan JS, Ngo HG, Totoro A, Singh AP, et al. Anti-CD47 monoclonal antibody-drug conjugate: a targeted therapy to treat triple-negative breast cancers. Vaccines. 2021;9(8):882.","journal-title":"Vaccines"},{"issue":"6","key":"1752_CR320","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304985","volume":"19","author":"M Sue","year":"2024","unstructured":"Sue M, Tsubaki T, Ishimoto Y, Hayashi S, Ishida S, Otsuka T, et al. Blockade of SIRP\u03b1-CD47 axis by anti-SIRP\u03b1 antibody enhances anti-tumor activity of DXd antibody-drug conjugates. PLoS ONE. 2024;19(6):e0304985.","journal-title":"PLoS ONE"},{"issue":"13","key":"1752_CR321","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1182\/blood-2003-05-1620","volume":"102","author":"WJ Kell","year":"2003","unstructured":"Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, et al. A feasibility study of simultaneous administration of Gemtuzumab Ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003;102(13):4277\u201383.","journal-title":"Blood"},{"issue":"1","key":"1752_CR322","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.leu.2404434","volume":"21","author":"AL Taksin","year":"2007","unstructured":"Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the Alfa group. Leukemia. 2007;21(1):66\u201371.","journal-title":"Leukemia"},{"issue":"4","key":"1752_CR323","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","volume":"29","author":"AK Burnett","year":"2011","unstructured":"Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of Gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369\u201377.","journal-title":"J Clin Oncol"},{"key":"1752_CR324","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood.V118.21.79.79","volume":"118","author":"J Delaunay","year":"2011","unstructured":"Delaunay J, Recher C, Pigneux A, Witz F, Ifrah N. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation: results of the GOELAMS AML 2006 IR study. Blood. 2011;118:37\u20138.","journal-title":"Blood"},{"issue":"32","key":"1752_CR325","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","volume":"30","author":"AK Burnett","year":"2012","unstructured":"Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924\u201331.","journal-title":"J Clin Oncol"},{"issue":"9825","key":"1752_CR326","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","volume":"379","author":"S Castaigne","year":"2012","unstructured":"Castaigne S, Pautas C, Terr\u00e9 C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of Gemtuzumab Ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508\u201316.","journal-title":"Lancet"},{"issue":"24","key":"1752_CR327","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","volume":"121","author":"SH Petersdorf","year":"2013","unstructured":"Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of Gemtuzumab Ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854\u201360.","journal-title":"Blood"},{"issue":"9","key":"1752_CR328","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of Gemtuzumab Ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986\u201396.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1752_CR329","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Tr\u00fcmper L, Iyer S, Advani R, et al. The ECHELON-2 trial: 5-year results of a randomized, phase III study of Brentuximab Vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288\u201398.","journal-title":"Ann Oncol"},{"issue":"6","key":"1752_CR330","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","volume":"8","author":"DJ Straus","year":"2021","unstructured":"Straus DJ, D\u0142ugosz-Danecka M, Connors JM, Alekseev S, Ill\u00e9s \u00c1, Picardi M, et al. Brentuximab Vedotin with chemotherapy for stage III or IV classical hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e410\u201321.","journal-title":"Lancet Haematol"},{"issue":"18","key":"1752_CR331","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","volume":"387","author":"SM Castellino","year":"2022","unstructured":"Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, et al. Brentuximab vedotin with chemotherapy in pediatric high-risk hodgkin\u2019s lymphoma. N Engl J Med. 2022;387(18):1649\u201360.","journal-title":"N Engl J Med"},{"issue":"30","key":"1752_CR332","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","volume":"36","author":"AM Evens","year":"2018","unstructured":"Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, et al. Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical hodgkin lymphoma. J Clin Oncol. 2018;36(30):3015\u201322.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1752_CR333","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaoncol.2024.0967","volume":"10","author":"NE Kopmar","year":"2024","unstructured":"Kopmar NE, Quach K, Gooley TA, Martino CH, Cherian S, Percival MM, et al. Dose-adjusted EPOCH plus inotuzumab ozogamicin in adults with relapsed or refractory B-cell ALL: a phase 1 dose-escalation trial. JAMA Oncol. 2024;10(7):961\u20135.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1752_CR334","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.3324\/haematol.2023.284409","volume":"109","author":"E Pennesi","year":"2024","unstructured":"Pennesi E, Brivio E, Ammerlaan ACJ, Jiang Y, Van der Velden VHJ, Beverloo HB, et al. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22\u2009+\u2009acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial. Haematologica. 2024;109(10):3157\u201366.","journal-title":"Haematologica"},{"issue":"36","key":"1752_CR335","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1200\/JCO.24.00490","volume":"42","author":"P Chevallier","year":"2024","unstructured":"Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, et al. Inotuzumab Ozogamicin and Low-Intensity chemotherapy in older patients with newly diagnosed CD22\u2009+\u2009Philadelphia Chromosome-Negative B-Cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2024;42(36):4327\u201341.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1752_CR336","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/bjh.14820","volume":"182","author":"NH Dang","year":"2018","unstructured":"Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2018;182(4):583\u20136.","journal-title":"Br J Haematol"},{"issue":"1","key":"1752_CR337","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/10428194.2021.1966780","volume":"63","author":"MC Pirosa","year":"2022","unstructured":"Pirosa MC, Zhang L, Hitz F, Novak U, Hess D, Terrot T, et al. A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas. Leuk Lymphoma. 2022;63(1):117\u201323.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1752_CR338","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351\u201363.","journal-title":"N Engl J Med"},{"issue":"11","key":"1752_CR339","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1182\/bloodadvances.2022009145","volume":"7","author":"RC Lynch","year":"2023","unstructured":"Lynch RC, Poh C, Ujjani CS, Warren EH, Smith SD, Shadman M, et al. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas. Blood Adv. 2023;7(11):2449\u201358.","journal-title":"Blood Adv"},{"issue":"9","key":"1752_CR340","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO-24-02242","volume":"43","author":"NL Bartlett","year":"2025","unstructured":"Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol. 2025;43(9):1061\u201372.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1752_CR341","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","volume":"7","author":"CS Diefenbach","year":"2020","unstructured":"Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, et al. Ipilimumab, nivolumab, and Brentuximab Vedotin combination therapies in patients with relapsed or refractory hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial. Lancet Haematol. 2020;7(9):e660\u201370.","journal-title":"Lancet Haematol"},{"issue":"3","key":"1752_CR342","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1182\/blood.2024024681","volume":"145","author":"HJ Lee","year":"2025","unstructured":"Lee HJ, Ramchandren R, Friedman J, Melear J, Flinn IW, Burke JM, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical hodgkin lymphoma. Blood. 2025;145(3):290\u20139.","journal-title":"Blood"},{"issue":"9","key":"1752_CR343","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1182\/blood.2022019536","volume":"143","author":"JW Friedberg","year":"2024","unstructured":"Friedberg JW, Bordoni R, Patel-Donnelly D, Larson T, Goldschmidt J, Boccia R, et al. Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy. Blood. 2024;143(9):786\u201395.","journal-title":"Blood"},{"issue":"5","key":"1752_CR344","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, et al. Belantamab Mafodotin, Pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024;391(5):408\u201321.","journal-title":"N Engl J Med"},{"issue":"15","key":"1752_CR345","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1002\/cncr.35319","volume":"130","author":"A Suvannasankha","year":"2024","unstructured":"Suvannasankha A, Bahlis N, Trudel S, Weisel K, Koenecke C, Oriol A, et al. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma. Cancer. 2024;130(15):2629\u201341.","journal-title":"Cancer"},{"issue":"7","key":"1752_CR346","doi-asserted-by":"publisher","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","volume":"10","author":"H D\u00f6hner","year":"2023","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, Fiedler W, K\u00fchn MWM, Schroeder T, et al. Intensive chemotherapy with or without Gemtuzumab Ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09\u201309): a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2023;10(7):e495\u2013509.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1752_CR347","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0691-7","volume":"18","author":"IE Krop","year":"2016","unstructured":"Krop IE, Modi S, LoRusso PM, Pegram M, Guardino E, Althaus B, et al. Phase 1b\/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res. 2016;18(1):34.","journal-title":"Breast Cancer Res"},{"issue":"7","key":"1752_CR348","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/annonc\/mdw157","volume":"27","author":"M Martin","year":"2016","unstructured":"Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib\/IIa study. Ann Oncol. 2016;27(7):1249\u201356.","journal-title":"Ann Oncol"},{"issue":"1","key":"1752_CR349","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19(1):115\u201326.","journal-title":"Lancet Oncol"},{"issue":"25","key":"1752_CR350","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.19.00882","volume":"37","author":"SA Hurvitz","year":"2019","unstructured":"Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, et al. Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study. J Clin Oncol. 2019;37(25):2206\u201316.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1752_CR351","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26019-y","volume":"12","author":"AS Clark","year":"2021","unstructured":"Clark AS, Yau C, Wolf DM, Petricoin EF, van \u2018t Veer LJ, Yee D, et al. Neoadjuvant T-DM1\/pertuzumab and paclitaxel\/trastuzumab\/pertuzumab for HER2\u2009+\u2009breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021;12(1):6428.","journal-title":"Nat Commun"},{"issue":"2","key":"1752_CR352","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III marianne study. J Clin Oncol. 2017;35(2):141\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1752_CR353","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/jamaoncol.2018.1812","volume":"4","author":"VF Borges","year":"2018","unstructured":"Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, et al. Tucatinib combined with Ado-Trastuzumab emtansine in advanced ERBB2\/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol. 2018;4(9):1214\u201320.","journal-title":"JAMA Oncol"},{"key":"1752_CR354","doi-asserted-by":"crossref","unstructured":"Hurvitz S, Vahdat L, Harbeck N, Wolff AC, Virginia F et al. Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer. Cancer Res 15 February 2021;81(4_Supplement):OT\u201328\u201301.","DOI":"10.1158\/1538-7445.SABCS20-OT-28-01"},{"key":"1752_CR355","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.2018.36.15_suppl.1035","volume":"36","author":"TA Patel","year":"2018","unstructured":"Patel TA, Ensor J, Rodriguez AA, Belcheva A, Darcourt JG, Niravath PA, et al. Phase Ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: stela results. J Clin Oncol. 2018;36:1035\u20131035.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1752_CR356","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11060-024-04681-8","volume":"168","author":"Y Koide","year":"2024","unstructured":"Koide Y, Nagai N, Adachi S, Ito M, Kawamura M, Ito M, et al. Impact of concurrent antibody-drug conjugates and radiotherapy on symptomatic radiation necrosis in breast cancer patients with brain metastases: a multicenter retrospective study. J Neurooncol. 2024;168(3):415\u201323.","journal-title":"J Neurooncol"},{"issue":"14","key":"1752_CR357","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","volume":"30","author":"A Bardia","year":"2024","unstructured":"Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, et al. Antibody-drug conjugate sacituzumab Govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer. Clin Cancer Res. 2024;30(14):2917\u201324.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1752_CR358","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s10549-018-4792-0","volume":"171","author":"S Jain","year":"2018","unstructured":"Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, et al. Phase I study of Alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast Cancer Res Treat. 2018;171(2):371\u201381.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1752_CR359","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1186-0","volume":"21","author":"TA Patel","year":"2019","unstructured":"Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, et al. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). Breast Cancer Res. 2019;21(1):100.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1752_CR360","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01823-8","volume":"26","author":"SA Jacobs","year":"2024","unstructured":"Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, et al. NSABP FB-10: a phase Ib\/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer. Breast Cancer Res. 2024;26(1):69.","journal-title":"Breast Cancer Res"},{"issue":"11","key":"1752_CR361","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.annonc.2024.07.245","volume":"35","author":"RA Freedman","year":"2024","unstructured":"Freedman RA, Heiling HM, Li T, Trapani D, Tayob N, Smith KL, et al. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: translational breast cancer research consortium trial 022. Ann Oncol. 2024;35(11):993\u20131002.","journal-title":"Ann Oncol"},{"issue":"8","key":"1752_CR362","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1001\/jamaoncol.2020.1796","volume":"6","author":"J Cort\u00e9s","year":"2020","unstructured":"Cort\u00e9s J, Di\u00e9ras V, Lorenzen S, Montemurro F, Riera-Knorrenschild J, Thuss-Patience P, et al. Efficacy and safety of trastuzumab emtansine plus capecitabine vs trastuzumab emtansine alone in patients with previously treated ERBB2 (HER2)-positive metastatic breast cancer: a phase 1 and randomized phase 2 trial. JAMA Oncol. 2020;6(8):1203\u20139.","journal-title":"JAMA Oncol"},{"issue":"10","key":"1752_CR363","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","volume":"21","author":"LA Emens","year":"2020","unstructured":"Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21(10):1283\u201395.","journal-title":"Lancet Oncol"},{"key":"1752_CR364","doi-asserted-by":"crossref","unstructured":"Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET 3rd, et al. Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. J Immunother Cancer. 2022;10(10):e005119.","DOI":"10.1136\/jitc-2022-005119"},{"issue":"24","key":"1752_CR365","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","volume":"30","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Mart\u00edn M, De Miguel MJ, et al. Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study. Clin Cancer Res. 2024;30(24):5548\u201358.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1752_CR366","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41591-024-03267-1","volume":"30","author":"RA Shatsky","year":"2024","unstructured":"Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024;30(12):3737\u201347.","journal-title":"Nat Med"},{"key":"1752_CR367","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241248336","volume":"16","author":"A Bardia","year":"2024","unstructured":"Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, et al. Tropion-breast03: a randomized phase III global trial of datopotamab deruxtecan\u2009\u00b1\u2009durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024;16:17588359241248336.","journal-title":"Ther Adv Med Oncol"},{"key":"1752_CR368","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251327992","volume":"17","author":"P Schmid","year":"2025","unstructured":"Schmid P, Oliveira M, O\u2019Shaughnessy J, Cristofanilli M, Graff SL, Im SA, et al. TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2025;17:17588359251327992.","journal-title":"Ther Adv Med Oncol"},{"key":"1752_CR369","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ygyno.2023.12.017","volume":"182","author":"MC Cristea","year":"2024","unstructured":"Cristea MC, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, et al. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FR\u03b1-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecol Oncol. 2024;182:124\u201331.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1752_CR370","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/ijgc-2022-003927","volume":"33","author":"AD Santin","year":"2023","unstructured":"Santin AD, Vergote I, Gonz\u00e1lez-Mart\u00edn A, Moore K, Oaknin A, Romero I, et al. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab Ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study. Int J Gynecol Cancer. 2023;33(4):562\u201370.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"1752_CR371","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","volume":"157","author":"DM O\u2019Malley","year":"2020","unstructured":"O\u2019Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, et al. Phase Ib study of Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020;157(2):379\u201385.","journal-title":"Gynecol Oncol"},{"key":"1752_CR372","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2024.01.045","volume":"185","author":"DL Richardson","year":"2024","unstructured":"Richardson DL, Moore KN, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, et al. Phase 1b study of Mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2024;185:186\u201393.","journal-title":"Gynecol Oncol"},{"issue":"36","key":"1752_CR373","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.23.00720","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote I, Van Nieuwenhuysen E, O\u2019Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, et al. Tisotumab Vedotin in combination with Carboplatin, Pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the InnovaTV 205\/GOG-3024\/ENGOT-cx8 study. J Clin Oncol. 2023;41(36):5536\u201349.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1752_CR374","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.22.00739","volume":"41","author":"DR Camidge","year":"2023","unstructured":"Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-Met protein-expressing non-small-cell lung cancer. J Clin Oncol. 2023;41(5):1105\u201315.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1752_CR375","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","volume":"36","author":"H Horinouchi","year":"2025","unstructured":"Horinouchi H, Cho BC, Camidge DR, Goto K, Tomasini P, Li Y, et al. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025;36(5):583\u201391.","journal-title":"Ann Oncol"},{"issue":"1","key":"1752_CR376","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/JCO.22.01643","volume":"41","author":"CJ Hoimes","year":"2023","unstructured":"Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41(1):22\u201331.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1752_CR377","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.22.02835","volume":"42","author":"P Grivas","year":"2024","unstructured":"Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, et al. Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3. J Clin Oncol. 2024;42(12):1415\u201325.","journal-title":"J Clin Oncol"},{"key":"1752_CR378","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1200\/JCO.2023.41.16_suppl.9004","volume":"41","author":"Y Goto","year":"2023","unstructured":"Goto Y, Su W-C, Levy BP, Rixe O, Yang T-Y, Tolcher AW, et al. TROPION-Lung02: datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). J Clin Oncol. 2023;41:9004\u20139004.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1752_CR379","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2217\/fon-2023-0230","volume":"19","author":"BP Levy","year":"2023","unstructured":"Levy BP, Felip E, Reck M, Yang JC, Cappuzzo F, Yoneshima Y, et al. TROPION-Lung08: phase III study of Datopotamab Deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 2023;19(21):1461\u201372.","journal-title":"Future Oncol"},{"issue":"37","key":"1752_CR380","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1080\/14796694.2024.2409621","volume":"20","author":"I Okamoto","year":"2024","unstructured":"Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, et al. Tropion-lung07: phase III study of Dato-DXd\u2009+\u2009pembrolizumab\u2009\u00b1\u2009platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol. 2024;20(37):2927\u201336.","journal-title":"Future Oncol"},{"issue":"12","key":"1752_CR381","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","volume":"9","author":"ES Lebow","year":"2023","unstructured":"Lebow ES, Pike LRG, Seidman AD, Moss N, Beal K, Yu Y. Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for brain metastases. JAMA Oncol. 2023;9(12):1729\u201333.","journal-title":"JAMA Oncol"},{"key":"1752_CR382","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101216","volume":"68","author":"L Zhang","year":"2025","unstructured":"Zhang L, Jin D, Zang J, Qian L, Zhang T, Wu Y, et al. Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study. Neoplasia. 2025;68:101216.","journal-title":"Neoplasia"},{"issue":"6","key":"1752_CR383","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1078-0432.CCR-24-3128","volume":"31","author":"HA Alqaisi","year":"2025","unstructured":"Alqaisi HA, Cohn DE, Chern JY, Duska LR, Jewell A, Corr BR, et al. Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant\/refractory high-grade ovarian cancer (NCI trial). Clin Cancer Res. 2025;31(6):993\u20131001.","journal-title":"Clin Cancer Res"},{"key":"1752_CR384","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00456","volume":"6","author":"TA Yap","year":"2022","unstructured":"Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, et al. Phase Ib SEASTAR study: combining rucaparib and sacituzumab govitecan in patients with cancer with or without mutations in homologous recombination repair genes. JCO Precis Oncol. 2022;6:e2100456.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"1752_CR385","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","volume":"36","author":"L Zhou","year":"2025","unstructured":"Zhou L, Yang KW, Zhang S, Yan XQ, Li SM, Xu HY, et al. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study. Ann Oncol. 2025;36(3):331\u20139.","journal-title":"Ann Oncol"},{"key":"1752_CR386","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107928","volume":"195","author":"AS Mansfield","year":"2024","unstructured":"Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, et al. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024;195:107928.","journal-title":"Lung Cancer"},{"issue":"1","key":"1752_CR387","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-21-1181","volume":"28","author":"S Rottey","year":"2022","unstructured":"Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, et al. Phase I\/IIa trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors. Clin Cancer Res. 2022;28(1):95\u2013105.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1752_CR388","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.cllc.2025.02.002","volume":"26","author":"LC Roisman","year":"2025","unstructured":"Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, et al. The PESGA trial: a prospective, open-label, single-arm, phase II study to evaluate first line therapy for Extensive-Stage small cell lung cancer (ES-SCLC) patients, treated by induction Carboplatin\/Etoposide\/Pembrolizumab followed by maintenance of Pembrolizumab\/ sacituzumab Govitecan. Clin Lung Cancer. 2025;26(4):267\u201370.","journal-title":"Clin Lung Cancer"},{"key":"1752_CR389","doi-asserted-by":"publisher","first-page":"TPS594","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS594","volume":"41","author":"Y Thomas Powles, Evan","year":"2023","unstructured":"Thomas Powles, Evan Y, Yu, Gopa Iyer MT, Campbell Y, Loriot M, De Santis, et al. Phase 2 clinical study evaluating the efficacy and safety of disitamab Vedotin with or without pembrolizumab in patients with HER2-expressing urothelial carcinoma (RC48G001). J Clin Oncol. 2023;41:TPS594.","journal-title":"J Clin Oncol"},{"key":"1752_CR390","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1200\/JCO.2023.41.6_suppl.521","volume":"41","author":"K Rohit","year":"2023","unstructured":"Rohit K, Jain Y, Yang J, Chadha MS, Chatwal JA, Kish S, Raymond, et al. Phase I\/II study of ipilimumab plus nivolumab combined with sacituzumab Govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma. J Clin Oncol. 2023;41:521\u2013521.","journal-title":"J Clin Oncol"},{"key":"1752_CR391","doi-asserted-by":"publisher","first-page":"TPS9146","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9146","volume":"40","author":"B Edward","year":"2022","unstructured":"Edward B, Garon SV, Liu SP, Owen M, Reck, Joel W, Neal D, Vicente, et al. EVOKE-02: A phase 2 study of sacituzumab Govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non\u2013small cell lung cancer (NSCLC). J Clin Oncol. 2022;40:TPS9146.","journal-title":"J Clin Oncol"},{"key":"1752_CR392","doi-asserted-by":"publisher","first-page":"TPS3158","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3158","volume":"41","author":"SN Hossein Borghaei","year":"2023","unstructured":"Hossein Borghaei SN, Waqar DS, Bruno S, Kitazono K, Wakuda AI, Spira, et al. TROPION-Lung04: phase 1b, multicenter study of Datopotamab Deruxtecan (Dato-DXd) in combination with immunotherapy\u2009\u00b1\u2009carboplatin in advanced\/metastatic non-small cell lung cancer (mNSCLC). J Clin Oncol. 2023;41:TPS3158.","journal-title":"J Clin Oncol"},{"key":"1752_CR393","volume":"41","author":"A Necchi","year":"2023","unstructured":"Necchi A, Bedke J, Galsky MD, Shore ND, Plimack ER, Xylinas E, et al. Phase 3 KEYNOTE-905\/EV-303: perioperative pembrolizumab (pembro) or pembro\u2009+\u2009enfortumab Vedotin (EV) for muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2023;41:TPS58.","journal-title":"J Clin Oncol"},{"key":"1752_CR394","doi-asserted-by":"publisher","first-page":"TPS579","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579","volume":"40","author":"A Thomas Powles","year":"2022","unstructured":"Thomas Powles A, Drakaki JY-C, Teoh E, Grande M, Fontes-Sousa C, Porta, et al. A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D)\u2009+\u2009tremelimumab (T)\u2009+\u2009enfortumab Vedotin (EV) or D\u2009+\u2009EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA). J Clin Oncol. 2022;40:TPS579.","journal-title":"J Clin Oncol"},{"key":"1752_CR395","doi-asserted-by":"publisher","first-page":"TPS4587","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4587","volume":"39","author":"J Christopher","year":"2021","unstructured":"Christopher J, Hoimes J, Bedke Y, Loriot H, Nishiyama X, Fang RS, Kataria, et al. KEYNOTE-B15\/EV-304: randomized phase 3 study of perioperative enfortumab Vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2021;39:TPS4587.","journal-title":"J Clin Oncol"},{"issue":"25","key":"1752_CR396","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","volume":"41","author":"PH O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, et al. Enfortumab Vedotin with or without pembrolizumab in Cisplatin-Ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol. 2023;41(25):4107\u201317.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1752_CR397","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jtho.2021.02.022","volume":"16","author":"J Malhotra","year":"2021","unstructured":"Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, et al. A phase 1\u20132 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC. J Thorac Oncol. 2021;16(9):1559\u201369.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1752_CR398","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","volume":"23","author":"RA Heiser","year":"2024","unstructured":"Heiser RA, Cao AT, Zeng W, Ulrich M, Younan P, Anderson ME, et al. Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity. Mol Cancer Ther. 2024;23(1):68\u201383.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1752_CR399","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","volume":"35","author":"BA McGregor","year":"2024","unstructured":"McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, et al. The double antibody drug conjugate (DAD) phase i trial: sacituzumab Govitecan plus enfortumab Vedotin for metastatic urothelial carcinoma. Ann Oncol. 2024;35(1):91\u20137.","journal-title":"Ann Oncol"},{"key":"1752_CR400","first-page":"LBA4012","volume":"43","author":"Z Lin Shen","year":"2025","unstructured":"Lin Shen Z, Peng C, Li L, Lu X, Wang J, Zhang, et al. Disitamab Vedotin (DV) plus Toripalimab (Tor) and chemotherapy (C)\/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la\/m) gastric cancer. J Clin Oncol. 2025;43:LBA4012.","journal-title":"J Clin Oncol"},{"key":"1752_CR401","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4519","volume":"43","author":"S Jiang","year":"2025","unstructured":"Jiang S, Guo H, Qu H, Bai Y, Shi B, Zhang P, et al. 9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with Toripalimab in treatment-na\u00efve patients with locally advanced or metastatic urothelial carcinoma (la\/mUC): results from a phase 1b\/2 study. J Clin Oncol. 2025;43:4519.","journal-title":"J Clin Oncol"},{"key":"1752_CR402","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2025.43.16_suppl.3002","volume":"43","author":"Y Huang","year":"2025","unstructured":"Huang Y, Zhang L, Ma Y, Zhao Y, Fang W, Zhao H, et al. Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC). J Clin Oncol. 2025;43:3002.","journal-title":"J Clin Oncol"},{"key":"1752_CR403","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1200\/JCO.2025.43.16_suppl.4017","volume":"43","author":"X Yu","year":"2025","unstructured":"Yu X, Ying J, Enxiao L, Zhou A, Sun Y, Yue J, et al. Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): results from a phase i dose expansion cohort evaluating IBI343. J Clin Oncol. 2025;43:4017.","journal-title":"J Clin Oncol"},{"key":"1752_CR404","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.106","volume":"43","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Sun L, Ren S, Pan F, Zhu H, Dang Q, et al. Phase 1 study of SHR-1826, a c-MET\u2013directed antibody-drug-conjugate (ADC), in advanced solid tumors. J Clin Oncol. 2025;43:106.","journal-title":"J Clin Oncol"},{"key":"1752_CR405","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1200\/JCO.2025.43.16_suppl.107","volume":"43","author":"M Runbo Zhong","year":"2025","unstructured":"Runbo Zhong M, Wang YQ, Hong H, Zhang Y. Phase 1 trial of SHR-A2102, a nectin-4\u2013directed antibody drug conjugate (ADC), in advanced solid tumors. J Clin Oncol. 2025;43:107.","journal-title":"J Clin Oncol"},{"key":"1752_CR406","first-page":"e13138","volume":"43","author":"J Herui Yao","year":"2025","unstructured":"Herui Yao J, Liu Y, Zeng Z, Huang J, Wang Y, Cao, et al. First-in-human study of JSKN016, a bispecific anti-TROP2\/HER3 antibody drug conjugate (ADC): antitumor activity in patients (pts) with metastatic triple-negative breast cancer (mTNBC) and safety results. J Clin Oncol. 2025;43:e13138.","journal-title":"J Clin Oncol"},{"key":"1752_CR407","unstructured":"Available at. https:\/\/www.gilead.com\/news\/news-details\/2025\/trodelvy-plus-keytruda-demonstrates-a-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-previously-untreated-pd-l1-metastatic-trip (accessed on July 12, 2025)."},{"key":"1752_CR408","unstructured":"Available at. https:\/\/www.prnewswire.com\/news-releases\/experimental-drug-development-centre-announces-the-presentation-of-updated-data-from-the-phase-1-study-of-antibody-drug-conjugate-ebc-129-at-the-2025-annual-meeting-of-the-american-society-of-clinical-oncology-asco-302467763.html(accessed on July 12, 2025)."}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01752-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:07:18Z","timestamp":1762171638000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01752-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":408,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1752"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01752-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}